| State of Incorporation: Florida |   | I.R.S. Employer Identification No. 27-1230588 |
|---------------------------------|--------|----------------------------------------------------|

|                            |   |                            |   |                                                                                                   |   |                              |
|---------------------------------|--------|---------------------------------|--------|--------------------------------------------------------------------------------------------------------|--------|-----------------------------------|
| Large accelerated filer ☐ |   |  Accelerated filer ☐ |   |              Non-accelerated filer ☐ |   | Smaller reporting company ☒ |
|                            |   |                            |   |                                                                                                   |   |                              |

----

TABLE OF CONTENTS

****

**TABLE OF CONTENTS**

|                      |   |                                                                                                              |   | Page   |
|---------------------------|--------|-------------------------------------------------------------------------------------------------------------------|--------|--------|
|                      |   |                                                                                                              |   |   |
| PART I                    |   |                                                                                                              |   | 3      |
|                      |   |                                                                                                              |   |   |
| Item 1.                   |   | Business                                                                                                          |   | 3      |
|                      |   |                                                                                                              |   |   |
| Item 1A.                  |   | Risk Factors                                                                                                      |   | 7      |
|                      |   |                                                                                                              |   |   |
| Item 1B.                  |   | Unresolved Staff Comments                                                                                         |   | 7      |
|                      |   |                                                                                                              |   |   |
| Item 2.                   |   | Properties                                                                                                        |   | 7      |
|                      |   |                                                                                                              |   |   |
| Item 3.                   |   | Legal Proceedings                                                                                                 |   | 8      |
|                      |   |                                                                                                              |   |   |
| Item 4.                   |   | Mine Safety Disclosures                                                                                           |   | 8      |
|                      |   |                                                                                                              |
| PART II                   |   |                                                                                                              |   | 8      |
|                      |   |                                                                                                              |   |   |
| Item 5.                   |   | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |   | 8      |
|                      |   |                                                                                                              |   |   |
| Item 6.                   |   | Selected Financial Data                                                                                           |   | 9      |
|                      |   |                                                                                                              |   |   |
| Item 7.                   |   | Management's Discussion and Analysis of Financial Condition and Results of Operations                             |   | 9      |
|                      |   |                                                                                                              |   |   |
| Item 7A.                  |   | Quantitative and Qualitative Disclosures about Market Risk                                                        |   | 20     |
|                      |   |                                                                                                              |   |   |
| Item 8.                   |   | Consolidated Financial Statements and Supplementary Data                                                          |   | 20     |
|                      |   |                                                                                                              |   |   |
| Item 9.                   |   | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                              |   | 20     |
|                      |   |                                                                                                              |   |   |
| Item 9A.                  |   | Controls and Procedures                                                                                           |   | 20     |
|                      |   |                                                                                                              |   |   |
| Item 9B.                  |   | Other Information                                                                                                 |   | 23     |
|                      |   |                                                                                                              |
| PART III                  |   |                                                                                                              |   | 23     |
|                      |   |                                                                                                              |   |   |
| Item 10.                  |   | Directors, Executive Officers and Corporate Governance                                                            |   | 23     |
|                      |   |                                                                                                              |   |   |
| Item 11.                  |   | Executive Compensation                                                                                            |   | 23     |
|                      |   |                                                                                                              |   |   |
| Item 12.                  |   | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                    |   | 23     |
|                      |   |                                                                                                              |   |   |
| Item 13.                  |   | Certain Relationships and Related Transactions, and Director Independence                                         |   | 23     |
|                      |   |                                                                                                              |   |   |
| Item 14.                  |   | Principal Accounting Fees and Services                                                                            |   | 23     |
|                      |   |                                                                                                              |
| PART IV                   |   |                                                                                                              |   | 24     |
|                      |   |                                                                                                              |   |   |
| Item 15.                  |   | Exhibits, Financial Statement Schedules                                                                           |   | 24     |
|                      |   |                                                                                                              |   |   |
| SIGNATURES                |   |                                                                                                              |
| EXHIBIT INDEX   |   |                                                                                                              |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

|                                |   | High   |   |   | Low    |   |
|-------------------------------------|--------|--------|--------|--------|--------|--------|
|                                |   |   |   |   |   |   |
| Fiscal Year Ended December 31, 2016 |   |   |   |   |   |   |
|                                |   |   |   |   |   |   |
| First Quarter                       |   | $      | 1.75   |   |   | $      | 1.09 |   |
| Second Quarter                      |   | $      | 1.38   |   |   | $      | 1.09 |   |
| Third Quarter                       |   | $      | 2.91   |   |   | $      | 1.02 |   |
| Fourth Quarter                      |   | $      | 1.82   |   |   | $      | 1.82 |   |
|                                |   |   |   |   |   |   |   |   |
| Fiscal Year Ended December 31, 2015 |   |   |   |   |   |   |   |   |
|                                |   |   |   |   |   |   |   |   |
| First Quarter                       |   | $      | 4.22   |   |   | $      | 0.73 |   |
| Second Quarter                      |   | $      | 2.04   |   |   | $      | 1.09 |   |
| Third Quarter                       |   | $      | 1.09   |   |   | $      | 1.09 |   |
| Fourth Quarter                      |   | $      | 1.60   |   |   | $      | 1.02 |   |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| (in thousands)                               |   | Year Ended December 31, |   |   |   |   |   |   |   |
|----------------------------------------------|--------|-------------------------|--------|--------|--------|--------|--------|--------|--------|
|                                         |   | 2016                    |   |   | 2015   |   |   | Change |   |   | % Change |   |
|                                         |   |                    |   |   |   |   |   |   |   |   |   |   |
| Product Development                          |   | $                       | 2,077  |   |   | $      | 141    |   |   | $ | 1,936 |   |   |   | 1,373.0 | % |
| Sales and marketing                          |   |                    | 733    |   |   |   | 123    |   |   |   | 610 |   |   |   | 495.9 | % |
| General and administrative                   |   |                    | 9,227  |   |   |   | 3,539  |   |   |   | 5,688 |   |   |   | 160.7 | % |
| Net loss from investment in LifeMed ID, Inc. |   |                    | 438    |   |   |   | -      |   |   |   | 438 |   |   |   | * |   |
| Gain on extinguishment of debt               |   |                    | (742   | )      |   |   | (404   | )      |   |   | (338 | ) |   |   | 83.7 | % |
| Interest Expense                             |   |                    | 3,027  |   |   |   | 494    |   |   |   | 2,533 |   |   |   | 512.8 | % |
|                                         |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| *Not meaningful                              |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

TABLE OF CONTENTS

| · | Our belief that we will begin to generate revenue from the sale of our LifeMed products through our direct sales and joint marketing and sales efforts under the Lenovo business partnership |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Our belief that sales of our Salamander products will increase through direct sales and regional technical centers in existing channels and that we may be able to add additional sales channels |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Our belief that we have the potential for business from our existing Agilivant revenue sharing arrangement |
|--------|------------------------------------------------------------------------------------------------------------|

| · | Our intent to focus our marketing and sales activities on the sale of additional instances of Agilivant software with revenue sharing terms |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------|

| · | Plans for additional development of existing products, including furtherance of our goal to leverage the interoperable capabilities of our products |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Our belief that expenditures relating to product development will not increase in material respects |
|--------|-----------------------------------------------------------------------------------------------------|

| · | Our belief that we will be able to control expenses, including costs for outside services and other general and administrative expenses |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------|

| · | Our intent to secure additional capital, either in the form of equity, debt or both, on terms acceptable to us |
|--------|---------------------------------------------------------------------------------------------------------------------|

----

TABLE OF CONTENTS

|                |   | Year Ended December 31, |   |   |   |   |   |   |   |
|---------------------|--------|-------------------------|--------|--------|--------|--------|--------|--------|--------|
|                |   | 2016                    |   |   | 2015   |   |   | Change |   |   | % Change |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total revenue       |   | $                       | 959    |   |   | $      | 245    |   |   | $ | 714 |   |   |   | 291.4 | % |
| Cost of sales       |   |                    | 206    |   |   |   | 32     |   |   |   | 174 |   |   |   | 543.8 | % |
| Gross margin        |   | $                       | 753    |   |   | $      | 213    |   |   | $ | 540 |   |   |   | 253.5 | % |
| Gross margin %      |   |                    | 78.5   | %      |   |   | 86.9   | %      |   |   |   |   |   |   |   |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Product Development |   | $                       | 680    |   |   | $      | 141    |   |   | $ | 539 |   |   |   | 382.3 | % |

|                |   | Year Ended December 31, |   |   |   |   |   |   |   |
|---------------------|--------|-------------------------|--------|--------|--------|--------|--------|--------|--------|
|                |   | 2016                    |   |   | 2015   |   |   | Change |   |   | % Change |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |
| Total revenue       |   | $                       | 1,234  |   |   | $      | -      |   |   | $ | 1,234 |   |   |   | * |   |
| Cost of sales       |   |                    | 16     |   |   |   | -      |   |   |   | 16 |   |   |   | * |   |
| Gross margin        |   | $                       | 1,218  |   |   | $      | -      |   |   | $ | 1,218 |   |   |   | * |   |
| Gross margin %      |   |                    | 98.7   | %      |   |   | *      | %      |   |   |   |   |   |   |   |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Product Development |   | $                       | 420    |   |   | $      | -      |   |   | $ | 420 |   |   |   | * |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| *Not meaningful     |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

TABLE OF CONTENTS

|                |   | Year Ended December 31, |   |   |   |   |   |   |   |
|---------------------|--------|-------------------------|--------|--------|--------|--------|--------|--------|--------|
|                |   | 2016                    |   |   | 2015   |   |   | Change |   |   | % Change |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |
| Total revenue       |   | $                       | 118    |   |   | $      | -      |   |   | $ | 118 |   |   |   | * |   |
| Cost of sales       |   |                    | 138    |   |   |   | -      |   |   |   | 138 |   |   |   | * |   |
| Gross margin        |   | $                       | (20    | )      |   | $      | -      |   |   | $ | (20 | ) |   |   | * |   |
| Gross margin %      |   |                    | -16.9  | %      |   |   | *      |   |   |   |   |   |   |   |   |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Product Development |   | $                       | 977    |   |   | $      | -      |   |   | $ | 977 |   |   |   | * |   |
|                |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| *Not meaningful     |   |                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

|                                      |   | Year Ended December 31, |   |
|-------------------------------------------|--------|-------------------------|--------|
|                                      |   | 2016                    |   |   | 2015 |   |
|                                      |   |                    |   |   |   |   |
| Other Financial Data:                     |   |                    |   |   |   |   |
| Net cash used in operating activities     |   | $                       | (4,237 | ) |   | $ | (1,939 | ) |
| Net cash used in investing activities     |   |                    | (3,409 | ) |   |   | (5,320 | ) |
| Net cash provided by financing activities |   |                    | 7,523  |   |   |   | 7,360 |   |

***Evaluation of Disclosure Controls and Procedures.***

******

|  | ● | pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------|

----

TABLE OF CONTENTS

|  | ● | provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors; and |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | ● | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Nuvel Holdings, Inc. did not have a full-time chief financial officer or a chief accounting officer. The Company availed itself of the services of a contract CFO firm for its required work.  The Company did not have an internal accounting department and relied on an outside accounting service to prepare financial statements and recording transactions. This was due to limited financial resources and limited staffing and resulted in the delay of recording and reporting certain transactions of the Company during the year ended December 31, 2015. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Nuvel Holdings, Inc. did not develop sufficient accounting policies and procedures, including the review and supervision, for all necessary areas or effectively communicate its existing policies to employees. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

TABLE OF CONTENTS

| · | Nuvel Holdings, Inc. did not have written documentation regarding internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and concluded that the control deficiency that resulted represented a material weakness. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Nuvel Holdings, Inc. had limited segregation of duties within its accounting and financial reporting functions. Segregation of duties within Nuvel Holdings, Inc. was limited due to limited financial resources and the small number of employees that were assigned to positions that involve the processing of financial information. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Nuvel Holdings, Inc. also identified a material weakness relating to the valuation of certain complex financial instruments issued during the period. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

***Management's Remediation Plan***

******

| ● | Increased oversight performed by our board of directors due to the expansion of the board of directors to eight members and the transition to our current Audit Committee comprised entirely of independent directors as defined under the rules of the New York Stock Exchange ("NYSE").                                                                                                                                                                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ● | A resulting increase in our Audit Committee's oversight role, including providing additional oversight of the Company's internal controls, more formal review of our consolidated financial statements, discussing complex or unusual accounting transactions with management and reviewing the draft periodic reports we file with the SEC.                                                                                                                                 |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ● | A more robust corporate governance structure including: (i) direct oversight of our internal controls by the Audit Committee of our board of directors; (ii) review of our annual report on Form 10-K by the Audit Committee of our board of directors prior to filing with the SEC; (iii) additional board of directors committees, including the Nominating and Governance Committee and the Compensation Committee;  and (iv) board of directors committee charters. |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ● | Completion of documentation of key accounting processes and internal controls, an internal assessment of the design and operating effectiveness of our internal controls, testing of the internal controls for effectiveness, resulting in remediation for proper compliance effectiveness.                                                                                                                                                                                  |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ● | A formalized financial reporting process that includes properly prepared, supported, reviewed and approved reconciliations of financial statement accounts; properly prepared, supported and reviewed journal entries; improved segregation of duties; and properly completed and approved financial closing checklists and a financial reporting calendar.                                                                                                                  |
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ● | Increased size of accounting staff and employment of individuals with the appropriate levels of technical accounting expertise enabling the Company to better segregate duties within its accounting and financial reporting functions.                                                                                                                                                                                                                                      |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| Item                                                       |   | Page(s) |
|------------------------------------------------------------|--------|---------|
|                                                       |   |    |
| Report of Independent Registered Public Accounting Firm    |   | 25      |
|                                                       |   |    |
| Consolidated Balance Sheets                                |   | 26 - 27 |
|                                                       |   |    |
| Consolidated Statements of Operations                      |   | 28      |
|                                                       |   |    |
| Consolidated Statements of Changes in Stockholders' Equity |   | 29 -30  |
|                                                       |   |    |
| Consolidated Statements of Cash Flows                      |   | 31 - 32 |
|                                                       |   |    |
| Notes to Consolidated Financial Statements                 |   | 33 - 65 |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| OrangeHook, Inc. and Subsidiaries                     |   |              |   |   |              |   |
|-------------------------------------------------------|--------|-------------------|--------|--------|-------------------|--------|
| Consolidated Balance Sheets                           |   |              |   |   |              |   |
| (in thousands)                                        |   |              |   |   |              |   |
|                                                  |   |              |   |   |              |   |
|                                                       |   | As of             |   |
|                                                  |   | December 31, 2016 |   |   | December 31, 2015 |   |
| Assets                                                |   |              |   |   |              |   |
| Current assets:                                       |   |              |   |   |              |   |
| Cash                                                  |   | $                 | 159    |   |              | $      | 282 |   |
| Accounts receivable                                   |   |              | 132    |   |              |   | 145 |   |
| Inventory                                             |   |              | 21     |   |              |   | 32 |   |
| Other current assets                                  |   |              | 294    |   |              |   | 106 |   |
| Total current assets                                  |   |              | 606    |   |              |   | 565 |   |
|                                                  |   |              |   |   |              |   |   |   |
| Furniture, equipment and leasehold improvements, net: |   |              | 455    |   |              |   | 127 |   |
| Other assets:                                         |   |              |   |   |              |   |   |   |
| Due from:                                             |   |              |   |   |              |   |   |   |
| Agilivant, LLC                                        |   |              | -      |   |              |   | 1,225 |   |
| Nuvel Holdings, Inc.                                  |   |              | -      |   |              |   | 856 |   |
| LifeMed ID, Inc.                                      |   |              | -      |   |              |   | 1,045 |   |
| Total other assets                                    |   |              | -      |   |              |   | 3,126 |   |
| Investment in LifeMed ID, Inc.                        |   |              | -      |   |              |   | 4,425 |   |
| Intangible assets, net of amortization                |   |              | 16,272 |   |              |   | 869 |   |
| Goodwill                                              |   |              | 12,302 |   |              |   | 1,567 |   |
| Other                                                 |   |              | 134    |   |              |   | - |   |
|                                                  |   |              | 28,708 |   |              |   | 9,987 |   |
| Total assets                                          |   | $                 | 29,769 |   |              | $      | 10,679 |   |

----

TABLE OF CONTENTS

| OrangeHook, Inc. and Subsidiaries                                           |   |              |    |   |              |   |
|-----------------------------------------------------------------------------|--------|-------------------|---------|--------|-------------------|--------|
| Consolidated Balance Sheets                                                 |   |              |    |   |              |   |
| (in thousands except for share and per share amounts)                       |   | As of             |    |
|                                                              |   | December 31, 2016 |    |   | December 31, 2015 |   |
| Liabilities and Stockholders' Equity                                        |   |              |    |   |              |   |
| Current liabilities:                                                        |   |              |    |   |              |   |
| Accounts payable                                                            |   | $                 | 3,754   |   |              | $      | 607 |   |
| Accrued compensation                                                        |   |              | 719     |   |              |   | 210 |   |
| Accrued dividends                                                           |   |              | 1,113   |   |              |   | 144 |   |
| Accrued Interest                                                            |   |              | 624     |   |              |   | 228 |   |
| Other accrued expenses                                                      |   |              | 1,622   |   |              |   | 426 |   |
| Current portion of capital lease obligation                                 |   |              | 119     |   |              |   | - |   |
| Current portion of deferred revenue                                         |   |              | 1,143   |   |              |   | 291 |   |
| Line of credit                                                              |   |              | 350     |   |              |   | - |   |
| Notes payable to directors, net of discount                                 |   |              | 2,793   |   |              |   | 218 |   |
| Convertible debentures, net of discount                                     |   |              | 3,337   |   |              |   | 383 |   |
| Other current debt                                                          |   |              | 1,361   |   |              |   | - |   |
| Total current liabilities                                                   |   | $                 | 16,935  |   |              | $      | 2,507 |   |
|                                                                        |   |              |    |   |              |   |   |   |
| Long-term liabilities                                                       |   |              |    |   |              |   |   |   |
| Capital lease obligation, less current portion                              |   | $                 | 171     |   |              | $      | - |   |
| Deferred revenue, noncurrent                                                |   |              | 2,602   |   |              |   | 32 |   |
| Put option obligation                                                       |   |              | 1,886   |   |              |   | - |   |
| Installment payable to related party                                        |   |              | 546     |   |              |   | - |   |
| Other long-term Liabilities (Earnout Shares)                                |   |              | 967     |   |              |   | - |   |
| Other long-term liabilities                                                 |   |              | 158     |   |              |   | - |   |
| Convertible debentures, net of discount- long-term                          |   |              | -       |   |              |   | 2,379 |   |
| Notes payable to directors, net of discount- long-term                      |   |              | -       |   |              |   | 2,058 |   |
| Total liabilities                                                           |   |              | 23,265  |   |              |   | 6,976 |   |
| Commitments and contingencies                                               |   |              |    |   |              |   |   |   |
| Stockholders' equity                                                        |   |              |    |   |              |   |   |   |
| Series A and Series A1 cumulative convertible redeemable preferred stock;   |   |
| authorized 9,000 and 6,000 shares; 0 and 6,188 shares issued           |   |
|    and outstanding; liquidation preference of $0 and $6,188  |   |              | -       |   |              |   | - |   |
| Series OH-2 cumulative convertible redeemable preferred stock;              |   |
| authorized 11,000 and 0 shares; 10,093 and 0 shares issued                  |   |
|    and outstanding; liquidation preference of $11,206 and $0 |   |              | -       |   |              |   | - |   |
| Series B cumulative preferred stock;                                        |   |              |    |   |              |   |   |   |
| authorized 200,000 and 0 shares; 20,000 and 0 shares issued                 |   |
| and outstanding; liquidation preference of $137 and $0                      |   |              | -       |   |              |   | - |   |
| Series C cumulative preferred stock;                                        |   |              |    |   |              |   |   |   |
| authorized 500,000 and 0 shares; 371,052 and 0 shares issued                |   |
| and outstanding; liquidation preference of $2,575 and $0                    |   |              | -       |   |              |   | - |   |
| Series D cumulative preferred stock;                                        |   |              |    |   |              |   |   |   |
| authorized 2,000,000 and 0 shares; 0 and 0 shares issued                    |   |
| and outstanding                                                             |   |              | -       |   |              |   | - |   |
| Common stock - Voting; $0.001 par value; authorized 100,000,000             |   |
| shares; 6,838,084 and 3,620,726 shares issued as of December 31, 2016 and   |   |
| 2015, respectively; 6,686,706 and 3,420,726 shares                          |   |              |    |   |              |
| outstanding as of December 31, 2016 and 2015, respectively                  |   |              | 7       |   |              |   | 3 |   |
| Additional paid-in capital                                                  |   |              | 22,143  |   |              |   | 8,142 |   |
| Preferred stock subscription receivable                                     |   |              | -       |   |              |   | (150 | ) |
| Accumulated deficit                                                         |   |              | (16,038 | )      |              |   | (4,292 | ) |
| Total stockholders' equity                                                  |   |              | 6,112   |   |              |   | 3,703 |   |
| Noncontrolling interest                                                     |   |              | 392     |   |              |   | - |   |
|                                                                        |   |              | 6,504   |   |              |   | 3,703 |   |
| Total liabilities and stockholders' equity                                  |   | $                 | 29,769  |   |              | $      | 10,679 |   |

----

TABLE OF CONTENTS

| OrangeHook, Inc. and Subsidiaries                             |   |                     |      |   |   |   |
|---------------------------------------------------------------|--------|--------------------------|-----------|--------|--------|--------|
| Consolidated Statements of Operations                         |   |                     |      |   |   |   |
| (in thousands, except for share and per share amounts)        |   |                     |      |   |   |   |
|                                                               |   | Years ended December 31, |      |
|                                                          |   | 2016                     |      |   | 2015   |   |
|                                                          |   |                     |      |   |   |   |
| Revenue                                                       |   | $                        | 2,311     |   |   | $      | 245 |   |
|                                                          |   |                     |      |   |   |   |   |   |
| Cost of sales (exclusive of depreciation and amortization)    |   |                     | 359       |   |   |   | 32 |   |
|                                                          |   |                     |      |   |   |   |   |   |
| Gross profit                                                  |   |                     | 1,952     |   |   |   | 213 |   |
|                                                          |   |                     |      |   |   |   |   |   |
| Operating expenses:                                           |   |                     |      |   |   |   |   |   |
| Product development                                           |   |                     | 2,077     |   |   |   | 141 |   |
| Sales and marketing                                           |   |                     | 733       |   |   |   | 123 |   |
| General and administrative                                    |   |                     | 9,227     |   |   |   | 3,539 |   |
|                                                          |   |                     |      |   |   |   |   |   |
| Total operating expenses                                      |   |                     | 12,037    |   |   |   | 3,803 |   |
|                                                          |   |                     |      |   |   |   |   |   |
| Loss from operations                                          |   |                     | (10,085   | )      |   |   | (3,590 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Other income (expense):                                       |   |                     |      |   |   |   |   |   |
|   Gain on debt extinguishment                       |   |                     | 742       |   |   |   | 404 |   |
|   Net loss on Investment in LifeMed ID, Inc.        |   |                     | (438      | )      |   |   | - |   |
|   Interest expense, net of interest income          |   |                     | (3,027    | )      |   |   | (494 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Loss before income taxes                                      |   |                     | (12,808   | )      |   |   | (3,680 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Income tax benefit                                            |   |                     | 2,122     |   |   |   | - |   |
|                                                          |   |                     |      |   |   |   |   |   |
| Net loss before non-controlling interest in subsidiary        |   |                     | (10,686   | )      |   |   | (3,680 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Non-controlling interest in subsidiary                        |   |                     | 89        |   |   |   | - |   |
|                                                          |   |                     |      |   |   |   |   |   |
| Net loss                                                      |   |                     | (10,775   | )      |   |   | (3,680 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Preferred stock dividends                                     |   |                     | (971      | )      |   |   | (405 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Net loss attributable to common stockholders                  |   | $                        | (11,746   | )      |   | $      | (4,085 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Loss per common share- basic and diluted                      |   | $                        | (2.51     | )      |   | $      | (2.31 | ) |
|                                                          |   |                     |      |   |   |   |   |   |
| Weighted average common shares outstanding- basic and diluted |   |                     | 4,687,039 |   |   |   | 1,766,030 |   |

----

TABLE OF CONTENTS

| OrangeHook Inc. and Subsidiaries                  |
|------------------------------------------------------------------------------------------------------------------------------|
| Consolidated Statements of Changes in Stockholders' Equity                                                                   |   |   |   |   |   |
| For the Years Ended December 31, 2016 and 2015              |
| (in thousands, except for share amounts)                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                                         |   | Series A and A-1 Preferred Stock |   | Series OH-2 Preferred Stock |   |   | Series B Preferred Stock |   | Series C Preferred Stock |   |
|                                                                                                                         |   | # Shares |   |   | Amount |   | # Shares |   | Amount |   |   | # Shares |   | Amount |   | # Shares |   | Amount |   |
| Balance, December 31, 2014                                                                                                   |   | 1,990 |   |   | $ | - |   | - |   | $ | - |   |   | - |   | $ | - |   | - |   | $ | - |   |
|                                                                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Sales of Series A preferred stock, net                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| of financing costs                                                                                                           |   | 4,198 |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Preferred stock subscription receivable                                                                                      |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock and options issued to                                                                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| directors for services                                                                                                       |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Stock warrants issued for services                                                                                           |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued to officers and                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| employees for services                                                                                                       |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Convertible debenture conversion                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| feature and warrants                                                                                                         |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for payment                                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| of dividends                                                                                                                 |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock warrants exercised                                                                                              |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for acquisition of                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Salamander Technologies, Inc.                                                                                                |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for debt                                                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| extinguishment                                                                                                               |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Net loss                                                                                                                     |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Dividends accrued on Series A                                                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| preferred stock                                                                                                              |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
|                                                                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, December 31, 2015                                                                                                   |   | 6,188 |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
|                                                                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Reverse merger with Nuvel Holdings, Inc.                                                                                     |   | (9,943 | ) |   |   | - |   | 9,943 |   |   | - |   |   | 20,000 |   |   | - |   | 371,052 |   |   | - |   |
| Stock based compensation - common                                                                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| stock issued to directors                                                                                                    |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Stock based compensation - common                                                                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| stock and options granted to employees                                                                                       |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Stock based compensation - warrants                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| granted to director                                                                                                          |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Warrants issued with notes payable                                                                                           |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Warrants issued with director loans                                                                                          |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Warrants issued with convertible debt                                                                                        |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Warrants issued for services                                                                                                 |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for exercise of                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| warrants                                                                                                                     |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for acquisition of                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Agilivant                                                                                                                    |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued in exchange for                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Agilivant debt                                                                                                               |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for acquisition of                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Life Nexus                                                                                                                   |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued in exchange for                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| notes payable                                                                                                                |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for acquisition of                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| LifeMed                                                                                                                      |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Common stock issued for services                                                                                             |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Sale of common stock                                                                                                         |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Sale of Series A and A-1 Preferred Stock                                                                                |   | 2,615 |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Sale of OH-2 Preferred Stock                                                                                                 |   | - |   |   |   | - |   | 150 |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Preferred stock issued for notes payable                                                                                     |   | 1,140 |   |   |   | -  |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Shares redeemed in exchange for                                                                                              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| receivable                                                                                                                   |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Proceeds from stock subscription                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| receivable                                                                                                                   |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Issuance of put option obligation                                                                                            |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Net loss                                                                                                                     |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
| Dividends accrued on Series OH-2                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Preferred Stock and Series A Preferred Stock                                                                                 |   | - |   |   |   | - |   | - |   |   | - |   |   | - |   |   | - |   | - |   |   | - |   |
|                                                                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, December 31, 2016                                                                                                   |   | - |   |   | $ | - |   | 10,093 |   | $ | - |   |   | 20,000 |   | $ | - |   | 371,052 |   | $ | - |   |

----

TABLE OF CONTENTS

| OrangeHook Inc. and Subsidiaries                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Consolidated Statements of Changes in Stockholders' Equity                      |
| For the Years Ended December 31, 2016 and 2015                        |
| (in thousands, except for share amounts)                         |
|                                                                                                                                                                                     |   | Common Stock |   | Additional Paid-In |   | PreferredStock Subscription |   | Accumulated |   | Total OrangeHook, |   | Non Controlling |   | Total |   |
|                                                                                                                                                                                     |   | # Shares |   | Amount |   | Capital |   | Receivable |   | Deficit |   | Inc. |   | Interest |   | Equity |   |
| Balance, December 31, 2014                                                                                                                                                               |   | 1,450,000 |   | $ | 1 |   | $ | 1,905 |   | $ | - |   | $ | (207 | ) | $ | 1,699 |   | $ | - |   | $ | 1,699 |   |
|                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Sales of Series A preferred stock, net                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| of financing costs                                                                                                                                                                       |   | - |   |   | - |   |   | 4,098 |   |   | - |   |   | - |   |   | 4,098 |   |   | - |   |   | 4,098 |   |
| Preferred stock subscription receivable                                                                                                                                                  |   | - |   |   | - |   |   | - |   |   | (150 | ) |   | - |   |   | (150 | ) |   | - |   |   | (150 | ) |
| Common stock and options issued to                                                                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| directors for services                                                                                                                                                                   |   | 100,000 |   |   | - |   |   | 633 |   |   | - |   |   | - |   |   | 633 |   |   | - |   |   | 633 |   |
| Stock warrants issued for services                                                                                                                                                       |   | - |   |   | - |   |   | 73 |   |   | - |   |   | - |   |   | 73 |   |   | - |   |   | 73 |   |
| Common stock issued to officers and                                                                                                                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| employees for services                                                                                                                                                                   |   | 1,500,000 |   |   | 2 |   |   | 239 |   |   | - |   |   | - |   |   | 241 |   |   | - |   |   | 241 |   |
| Convertible debenture conversion                                                                                                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| feature and warrants                                                                                                                                                                     |   | - |   |   | - |   |   | 414 |   |   | - |   |   | - |   |   | 414 |   |   | - |   |   | 414 |   |
| Common stock issued for payment                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| of dividends                                                                                                                                                                             |   | 28,583 |   |   | - |   |   | 200 |   |   | - |   |   | - |   |   | 200 |   |   | - |   |   | 200 |   |
| Common stock warrants exercised                                                                                                                                                          |   | 160,000 |   |   | - |   |   | 1 |   |   | - |   |   | - |   |   | 1 |   |   | - |   |   | 1 |   |
| Common stock issued for acquisition of                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Salamander Technologies, Inc.                                                                                                                                                            |   | 144,846 |   |   | - |   |   | 460 |   |   | - |   |   | - |   |   | 460 |   |   | - |   |   | 460 |   |
| Common stock issued for debt                                                                                                                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| extinguishment                                                                                                                                                                           |   | 37,297 |   |   | - |   |   | 119 |   |   | - |   |   | - |   |   | 119 |   |   | - |   |   | 119 |   |
| Net loss                                                                                                                                                                                 |   | - |   |   | - |   |   | - |   |   | - |   |   | (3,680 | ) |   | (3,680 | ) |   | - |   |   | (3,680 | ) |
| Dividends accrued on Series A                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| preferred stock                                                                                                                                                                          |   | - |   |   | - |   |   | - |   |   | - |   |   | (405 | ) |   | (405 | ) |   | - |   |   | (405 | ) |
|                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, December 31, 2015                                                                                                                                                               |   | 3,420,726 |   |   | 3 |   |   | 8,142 |   |   | (150 | ) |   | (4,292 | ) |   | 3,703 |   |   | - |   |   | 3,703 |   |
|                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Reverse merger with Nuvel Holdings, Inc.                                                                                                                                                 |   | 458,767 |   |   | 1 |   |   | 1,655 |   |   | - |   |   | - |   |   | 1,656 |   |   | - |   |   | 1,656 |   |
| Stock based compensation - common                                                                                                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| stock issued to directors                                                                                                                                                                |   | 200,000 |   |   | - |   |   | 32 |   |   | - |   |   | - |   |   | 32 |   |   | - |   |   | 32 |   |
| Stock based compensation - common                                                                                                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| stock and options granted to employees                                                                                                                                                   |   | 50,000 |   |   | - |   |   | 475 |   |   | - |   |   | - |   |   | 475 |   |   | - |   |   | 475 |   |
| Stock based compensation - warrants                                                                                                                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| granted to director                                                                                                                                                                      |   | - |   |   | - |   |   | 259 |   |   | - |   |   | - |   |   | 259 |   |   | - |   |   | 259 |   |
| Warrants issued with notes payable                                                                                                                                                       |   | - |   |   | - |   |   | 87 |   |   | - |   |   | - |   |   | 87 |   |   | - |   |   | 87 |   |
| Warrants issued with director loans                                                                                                                                                      |   | - |   |   | - |   |   | 198 |   |   | - |   |   | - |   |   | 198 |   |   | - |   |   | 198 |   |
| Warrants issued with convertible debt                                                                                                                                                    |   | - |   |   | - |   |   | 128 |   |   | - |   |   | - |   |   | 128 |   |   | - |   |   | 128 |   |
| Warrants issued for services                                                                                                                                                             |   | - |   |   | - |   |   | 7 |   |   | - |   |   | - |   |   | 7 |   |   | - |   |   | 7 |   |
| Common stock issued for exercise of                                                                                                                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| warrants                                                                                                                                                                                 |   | 105,000 |   |   | - |   |   | 9 |   |   | - |   |   | - |   |   | 9 |   |   | - |   |   | 9 |   |
| Common stock issued for acquisition of                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Agilivant                                                                                                                                                                                |   | 282,173 |   |   | - |   |   | 897 |   |   | - |   |   | - |   |   | 897 |   |   | 303 |   |   | 1,200 |   |
| Common stock issued in exchange for                                                                                                                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Agilivant debt                                                                                                                                                                           |   | 70,997 |   |   | - |   |   | 226 |   |   | - |   |   | - |   |   | 226 |   |   | - |   |   | 226 |   |
| Common stock issued for acquisition of                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Life Nexus                                                                                                                                                                               |   | 178,571 |   |   | - |   |   | 568 |   |   | - |   |   | - |   |   | 568 |   |   | - |   |   | 568 |   |
| Common stock issued in exchange for                                                                                                                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| notes payable                                                                                                                                                                            |   | 387,912 |   |   | 1 |   |   | 1,243 |   |   | - |   |   | - |   |   | 1,244 |   |   | - |   |   | 1,244 |   |
| Common stock issued for acquisition of                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| LifeMed                                                                                                                                                                                  |   | 1,454,261 |   |   | 2 |   |   | 4,623 |   |   | - |   |   | - |   |   | 4,625 |   |   | - |   |   | 4,625 |   |
| Common stock issued for services                                                                                                                                                         |   | 6,513 |   |   | - |   |   | 21 |   |   | - |   |   | - |   |   | 21 |   |   | - |   |   | 21 |   |
| Sale of common stock                                                                                                                                                                     |   | 78,000 |   |   | - |   |   | 250 |   |   | - |   |   | - |   |   | 250 |   |   | - |   |   | 250 |   |
| Sale of Series A and A-1 Preferred Stock                                                                                                                                                 |   | - |   |   | - |   |   | 2,539 |   |   | - |   |   | - |   |   | 2,539 |   |   | - |   |   | 2,539 |   |
| Conversion of director loans into preferred stock                                                                                                                                        |   | - |   |   | - |   |   | - |   |   | - |   |   | - |   |   | 1,140 |   |   | - |   |   | 1,140 |   |
| Sale of OH-2 Preferred Stock                                                                                                                                                             |   | - |   |   | - |   |   | 150 |   |   | - |   |   | - |   |   | 150 |   |   | - |   |   | 150 |   |
| Shares redeemed in exchange for                                                                                                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| receivable                                                                                                                                                                               |   | (6,214 | ) |   | - |   |   | (20 | ) |   | - |   |   | - |   |   | (20 | ) |   | - |   |   | (20 | ) |
| Proceeds from stock subscription                                                                                                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| receivable                                                                                                                                                                               |   | - |   |   | - |   |   | - |   |   | 150 |   |   | - |   |   | 150 |   |   | - |   |   | 150 |   |
| Issuance of put option obligation                                                                                                                                                        |   | - |   |   | - |   |   | (486 | ) |   | - |   |   | - |   |   | (486 | ) |   | - |   |   | (486 | ) |
| Net loss                                                                                                                                                                                 |   | - |   |   | - |   |   | - |   |   | - |   |   | (10,775 | ) |   | (10,775 | ) |   | 89 |   |   | (10,686 | ) |
| Dividends accrued on Series OH-2                                                                                                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Preferred Stock and Series A Preferred Stock                                                                                                                                             |   | - |   |   | - |   |   | - |   |   | - |   |   | (971 | ) |   | (971 | ) |   | - |   |   | (971 | ) |
|                                                                                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, December 31, 2016                                                                                                                                                               |   | 6,686,706 |   | $ | 7 |   | $ | 22,143 |   | $ | - |   | $ | (16,038 | ) | $ | 6,112 |   | $ | 392 |   | $ | 6,504 |   |

----

TABLE OF CONTENTS

| OrangeHook, Inc. and Subsidiaries                                                    |   |                     |    |   |   |   |
|--------------------------------------------------------------------------------------|--------|--------------------------|---------|--------|--------|--------|
| Consolidated Statements of Cash Flows                                                |   |                     |    |   |   |   |
| (in thousands)                                                                       |   |                     |    |   |   |   |
|                                                                                 |   | Years Ended December 31, |    |
|                                                                                 |   | 2016                     |    |   | 2015   |   |
| Cash flows used for operating activities                                             |   |                     |    |   |   |   |
| Net loss                                                                             |   | $                        | (10,775 | )      |   | $      | (3,680 | ) |
| Adjustments to reconcile net loss to net cash from                                   |   |                     |    |   |   |   |   |   |
| operating activities:                                                                |   |                     |    |   |   |   |   |   |
| Interest on forward purchase contract                                                |   |                     | 1,465   |   |   |   | - |   |
| Stock-based compensation                                                             |   |                     | 766     |   |   |   | 917 |   |
| Stock and options issued for services                                                |   |                     | 28      |   |   |   | - |   |
| Amortization of cash conversion feature and warrants on convertible debentures       |   |                     | 250     |   |   |   | 215 |   |
| Amortization of original issue discount on short-term debt                           |   |                     | 87      |   |   |   | - |   |
| Amortization of original issue discount on director loans                            |   |                     | 198     |   |   |   | - |   |
| Amortization of debt issuance costs                                                  |   |                     | 103     |   |   |   | 94 |   |
| Net loss from investment in LifeMed ID, Inc.                                         |   |                     | 438     |   |   |   | - |   |
| Gain on debt extinguishment                                                          |   |                     | (742    | )      |   |   | (404 | ) |
| Non-controlling interest in subsidiary                                               |   |                     | 89      |   |   |   | - |   |
| Depreciation and amortization                                                        |   |                     | 1,249   |   |   |   | 40 |   |
| Interest earned on due from receivables                                              |   |                     | (24     | )      |   |   | (62 | ) |
| Income tax benefit related to deferred taxes                                         |   |                     | (2,122  | )      |   |   | - |   |
| Changes in operating assets and liabilities:                                         |   |                     |    |   |   |   |   |   |
| Accounts receivable                                                                  |   |                     | 41      |   |   |   | 100 |   |
| Inventory                                                                            |   |                     | 11      |   |   |   | (10 | ) |
| Other current assets                                                                 |   |                     | (142    | )      |   |   | 8 |   |
| Accounts payable                                                                     |   |                     | 1,094   |   |   |   | 266 |   |
| Accrued expenses                                                                     |   |                     | 1,109   |   |   |   | 585 |   |
| Deferred revenue                                                                     |   |                     | 2,640   |   |   |   | (8 | ) |
| Net cash flows used for operating activities                                         |   |                     | (4,237  | )      |   |   | (1,939 | ) |
| Cash flows used for investing activities                                             |   |                     |    |   |   |   |   |   |
| Advances to Agilivant, LLC                                                           |   |                     | (85     | )      |   |   | (1,006 | ) |
| Advances to Nuvel Holdings, Inc.                                                     |   |                     | (675    | )      |   |   | (699 | ) |
| Advances to Salamander Technologies, Inc.                                            |   |                     | -       |   |   |   | (492 | ) |
| Advances to LifeMed ID, Inc.                                                         |   |                     | (1,359  | )      |   |   | (1,045 | ) |
| Payments from Salamander Technologies, Inc.                                          |   |                     | -       |   |   |   | 230 |   |
| Payments from Agilivant, LLC                                                         |   |                     | -       |   |   |   | 1 |   |
| Payments from LifeMed ID, Inc.                                                       |   |                     | 1       |   |   |   | - |   |
| Decrease (increase) in restricted cash                                               |   |                     | -       |   |   |   | 137 |   |
| Purchase of Salamander Technologies, Inc. stock for cash, net of cash received of $6 |   |                     | -       |   |   |   | (443 | ) |
| Purchase of Agilivant, LLC member units for stock, net of cash received of $9        |   |                     | 9       |   |   |   | - |   |
| Purchase of LifeMed ID, Inc. net of cash received of $130                            |   |                     | 130     |   |   |   | - |   |
| Purchase of Nuvel Holdings, Inc. net of cash received of $8                          |   |                     | 8       |   |   |   | - |   |
| Purchase of LifeMed ID, Inc. preferred and common stock                              |   |                     | (1,310  | )      |   |   | (1,925 | ) |
| Costs incurred in acquisition of LifeNexus assets                                    |   |                     | (19     | )      |   |   | - |   |
| Purchases of fixed assets                                                            |   |                     | (109    | )      |   |   | (78 | ) |
| Net cash flows used for investing activities                                         |   |                     | (3,409  | )      |   |   | (5,320 | ) |

----

TABLE OF CONTENTS

| OrangeHook, Inc. and Subsidiaries                                      |   |                     |   |   |   |   |
|------------------------------------------------------------------------|--------|--------------------------|--------|--------|--------|--------|
| Consolidated Statements of Cash Flows                                  |   |                     |   |   |   |   |
| (in thousands)                                                         |   |                     |   |   |   |   |
|                                                                   |   | Years Ended December 31, |   |
|                                                                   |   | 2016                     |   |   | 2015   |   |
| Cash flows provided by financing activities                            |   |                     |   |   |   |   |
| Proceeds from director loans                                           |   | $                        | 2,255  |   |   | $      | 950 |   |
| Proceeds from sale of preferred stock, net of expenses                 |   |                     | 2,689  |   |   |   | 3,948 |   |
| Proceeds from sale of convertible debentures                           |   |                     | 600    |   |   |   | 3,050 |   |
| Proceeds from short-term debt                                          |   |                     | 3,873  |   |   |   | - |   |
| Proceeds from stock subscription receivable                            |   |                     | 150    |   |   |   | - |   |
| Proceeds from sale of common stock                                     |   |                     | 250    |   |   |   | - |   |
| Debt issuance costs                                                    |   |                     | (28    | )      |   |   | (153 | ) |
| Borrowings on line of credit                                           |   |                     | 2,538  |   |   |   | - |   |
| Payments on line of credit                                             |   |                     | (2,188 | )      |   |   | (200 | ) |
| Exercise of stock warrants                                             |   |                     | 9      |   |   |   | 1 |   |
| Payments on director loans                                             |   |                     | (660   | )      |   |   | (154 | ) |
| Payments of convertible debentures                                     |   |                     | (448   | )      |   |   | - |   |
| Payments of notes payable                                              |   |                     | (18    | )      |   |   | - |   |
| Payments on short-term debt                                            |   |                     | (1,487 | )      |   |   | - |   |
| Payments of capital lease obligations                                  |   |                     | (12    | )      |   |   | - |   |
| Payments of preferred stock dividends                                  |   |                     | -      |   |   |   | (82 | ) |
| Net cash flows provided by financing activities                        |   |                     | 7,523  |   |   |   | 7,360 |   |
| Net increase (decrease) in cash                                        |   |                     | (123   | )      |   |   | 100 |   |
| Cash                                                                   |   |                     |   |   |   |   |   |   |
| Beginning of year                                                      |   |                     | 282    |   |   |   | 182 |   |
| End of year                                                            |   | $                        | 159    |   |   | $      | 282 |   |
|                                                                   |   |                     |   |   |   |   |   |   |
| Supplemental disclosure of cashflow information:                       |   |                     |   |   |   |   |   |   |
| Interest paid                                                          |   | $                        | 528    |   |   | $      | - |   |
| Taxes paid                                                             |   |                     | -      |   |   |   | - |   |
|                                                                   |   |                     |   |   |   |   |   |   |
| Supplemental disclosure of noncash financing activities:               |   |                     |   |   |   |   |   |   |
| Financing fees accrued for issuance of warrants                        |   | $                        | -      |   |   | $      | 2 |   |
| Preferred stock dividends paid in stock                                |   |                     | -      |   |   |   | 200 |   |
| Common stock issued for acquisition of Salamander Technologies, Inc.   |   |                     | -      |   |   |   | 460 |   |
| Common stock issued for acquisition of Agilivant, LLC                  |   |                     | 897    |   |   |   | - |   |
| Common stock issued for acquisition of LifeNexus assets                |   |                     | 568    |   |   |   | - |   |
| Common stock issued for acquisition of LifeMed ID, Inc.                |   |                     | 4,625  |   |   |   | - |   |
| Common stock issued for acquisition of Nuvel Holdings, Inc.            |   |                     | 1,656  |   |   |   | - |   |
| Common stock issued to retire debt                                     |   |                     | 1,470  |   |   |   | 119 |   |
| Common stock cancelled in exchange for receivable                      |   |                     | (20    | )      |   |   | - |   |
| Original issue discount for warrants and beneficial conversion feature |   |                     | 413    |   |   |   | 414 |   |
| Preferred stock receiveable for issuance of preferred stock            |   |                     | -      |   |   |   | 150 |   |
| Director options for debt issuance costs                               |   |                     | -      |   |   |   | 29 |   |
| Accrued dividends on preferred stock                                   |   |                     | 971    |   |   |   | 144 |   |
| Conversion of director loan into preferred stock                       |   |                     | 1,140  |   |   |   | - |   |
| Put option obligation to related party- fair value of common stock     |   |                     | 486    |   |   |   | - |   |
| Installment payable to related party- fair value of common stock       |   |                     | 546    |   |   |   | - |   |
| Accrued interest converted to convertible debentures                   |   |                     | 226    |   |   |   | - |   |
| Capital lease additions                                                |   |                     | 246    |   |   |   | - |   |

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

| Current assets                         |   | $      | 16     |   |
|----------------------------------------|--------|--------|--------|--------|
| Software technology                    |   |   | 5,824  |   |
| Goodwill                               |   |   | 2,616  |   |
| Current Liabilities                    |   |   | (1,529 | )      |
| Deferred Tax Liability                 |   |   | (2,122 | )      |
| Assumed Obligations to OrangeHook Inc. |   |   | (1,562 | )      |
| Assumed Debt                           |   |   | (620   | )      |
| Contingent Consideration               |   |   | (967   | )      |
|                                   |   |   |   |   |
| Value of net assets acquired           |   | $      | 1,656  |   |

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

| Current assets                   |   | $      | 206    |   |
|----------------------------------|--------|--------|--------|--------|
| Property and Equipment           |   |   | 21     |   |
| Other Assets                     |   |   | 108    |   |
| Intangible assets:               |   |   |   |   |
| Marketing asset portfolio        |   |   | 350    |   |
| Software technology              |   |   | 4,600  |   |
| Customer relationships           |   |   | 3,960  |   |
| Goodwill                         |   |   | 4,960  |   |
| Cash paid prior to merger        |   |   | (6,376 | )      |
| Due to dissenter                 |   |   | (196   | )      |
| Assumed obligation to OrangeHook |   |   | (1,358 | )      |
| Current Liabilities              |   |   | (1,549 | )      |
| Assumed Debt                     |   |   | (103   | )      |
| Value of net assets acquired     |   | $      | 4,623  |   |

| Risk-free interest rate      |   |   | 2.1   | %      |
|------------------------------|--------|--------|-------|--------|
| Expected volatility          |   |   | 100.0 | %      |
| Dividend yield               |   |   | 0.0   | %      |
| Expected option life (years) |   |   | 7     |   |

| Risk-free interest rate      |   |   | 2.0  | %      |
|------------------------------|--------|--------|------|--------|
| Expected volatility          |   |   | 36.1 | %      |
| Dividend yield               |   |   | 0.0  | %      |
| Expected option life (years) |   |   | 7    |   |

----

TABLE OF CONTENTS

----

| Tangible assets              |   | $      | -      |   |
|------------------------------|--------|--------|--------|--------|
| Intangible assets:           |   |   |   |   |
| Trademarks and Patents  |   |   | 25     |   |
| Software technology          |   |   | 562    |   |
| Value of net assets acquired |   | $      | 587    |   |

----

TABLE OF CONTENTS

----

| Current assets               |   | $      | 56     |   |
|------------------------------|--------|--------|--------|--------|
| Intangible assets:           |   |   |   |   |
| Trademarks                   |   |   | 189    |   |
| Software technology          |   |   | 1,038  |   |
| Customer relationships       |   |   | 45     |   |
| Goodwill                     |   |   | 3,159  |   |
| Current Liabilities          |   |   | (587   | )      |
| Assumed debt                 |   |   | (2,218 | )      |
|                         |   |   | 1,682  |   |
| Noncontrolling interest      |   |   | (303   | )      |
| Value of net assets acquired |   | $      | 1,379  |   |

----

TABLE OF CONTENTS

----

| Cash                         |   | $      | 6      |   |
|------------------------------|--------|--------|--------|--------|
| Accounts receivable          |   |   | 243    |   |
| Other current assets         |   |   | 36     |   |
| Fixed assets                 |   |   | 34     |   |
| Intangible assets:           |   |   |   |   |
| Trade name                   |   |   | 891    |   |
| Goodwill                     |   |   | 1,567  |   |
| Accounts payable             |   |   | (210   | )      |
| Accrued expenses             |   |   | (149   | )      |
| Deferred revenue             |   |   | (332   | )      |
| Line of credit               |   |   | (200   | )      |
| Other debt                   |   |   | (925   | )      |
| Value of net assets acquired |   | $      | 961    |   |

|                |   | Gross Revenue      |   |
|---------------------|--------|--------------------|--------|
|                |   | Royalty Percentage |   |
| 2014 through 2017   |   |               | 5      | % |
| 2018 through 2019   |   |               | 3      | % |
| 2020 and thereafter |   |               | 2      | % |

----

TABLE OF CONTENTS

----

|                                                        |   | As of December 31, |   |
|-------------------------------------------------------------|--------|--------------------|--------|
|                                                        |   | 2016               |   |   | 2015 |   |
|                                                        |   |               |   |   |   |   |
| Furniture and equipment                                     |   | $                  | 129    |   |   | $ | 88 |   |
| Furniture and equipment acquired under capital lease        |   |               | 247    |   |   |   | - |   |
| Computer Software                                           |   |               | 51     |   |   |   | 22 |   |
| Leasehold improvements                                      |   |               | 104    |   |   |   | 35 |   |
|                                                        |   |               | 531    |   |   |   | 145 |   |
| Less accumulated depreciation and amortization              |   |               | (76    | ) |   |   | (18 | ) |
| Total  furniture, equipment and leasehold improvements |   | $                  | 455    |   |   | $ | 127 |   |

|                        |   | Corporate |   |   | Sal-Tech |   |   | AGL    |   |   | LMID  |   |   | Total  |   |
|----------------------------------|--------|-----------|--------|--------|----------|--------|--------|--------|--------|--------|-------|--------|--------|--------|--------|
| Balances as of December 31, 2015 |   | $         | -      |   |     | $      | 1,567  |   |   | $      | -     |   |   | $      | -      |   |   | $ | 1,567 |   |
| Acquisitions                     |   |      | 2,616  |   |     |   | -      |   |   |   | 3,159 |   |   |   | 4,960  |   |   |   | 10,735 |   |
| Balances as of December 31, 2016 |   | $         | 2,616  |   |     | $      | 1,567  |   |   | $      | 3,159 |   |   | $      | 4,960  |   |   | $ | 12,302 |   |

----

TABLE OF CONTENTS

----

|                                              |   | December 31, 2016 |   |
|--------------------------------------------------------|--------|-------------------|--------|
|                                                   |   |              |   |   | Accumulated |   |   |   |   |   |   |   |   | Estimated |   |
|                                                   |   | Cost              |   |   | Amortization |   |   | Impairment |   |   | Net |   |   | Useful Lives |   |
|                                                   |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Definite-life intangibles                              |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Trademarks, patents and marketing asset portfolio |   | $                 | 564    |   |   | $ | (34 | ) |   | $ | - |   |   | $ | 530 |   |   | 10 years |   |
| Tradenames                                             |   |              | 891    |   |   |   | (111 | ) |   |   | - |   |   |   | 780 |   |   | 10 years |   |
| Software technology                                    |   |              | 12,024 |   |   |   | (706 | ) |   |   | - |   |   |   | 11,318 |   |   | 5 - 10 years |   |
| Customer relationships                                 |   |              | 4,005  |   |   |   | (361 | ) |   |   | - |   |   |   | 3,644 |   |   | 5 years |   |
| Total  intangible assets                          |   | $                 | 17,484 |   |   | $ | (1,212 | ) |   | $ | - |   |   | $ | 16,272 |   |   |   |   |

|                     |   | December 31, 2015 |   |
|-------------------------------|--------|-------------------|--------|
|                          |   |              |   |   | Accumulated |   |   |   |   |   |   |   |   | Estimated |   |
|                          |   | Cost              |   |   | Amortization |   |   | Impairment |   |   | Net |   |   | Useful Lives |   |
|                          |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Definite-life intangibles     |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Tradenames                    |   | $                 | 891    |   |   | $ | (22 | ) |   | $ | - |   |   | $ | 869 |   |   | 10 years |   |
| Total  intangible assets |   | $                 | 891    |   |   | $ | (22 | ) |   | $ | - |   |   | $ | 869 |   |   |   |   |

| 2017       |   | $      | 2,834 |   |
|------------|--------|--------|-------|--------|
| 2018       |   |   | 2,834 |   |
| 2019       |   |   | 2,834 |   |
| 2020       |   |   | 2,834 |   |
| 2021       |   |   | 1,820 |   |
| Thereafter |   |   | 3,116 |   |

| · | Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets. |
|--------|-----------------------------------------------------------------------------------------------------|

| · | Level 2 - Valuations based on observable inputs (other than Level 1 prices), such as quoted prices for similar assets at the measurement date; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Level 3 - Valuations based on inputs that are unobservable and involve management judgment and the reporting entity's own assumptions about market participants and pricing. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

TABLE OF CONTENTS

----

|                                 |   | Fair Value as of December 31, 2016 |   |   | Fair Value as of December 31, 2015 |   |
|--------------------------------------|--------|------------------------------------|--------|--------|------------------------------------|--------|
|                                 |   | Level 1                            |   |   | Level 2                            |   |   | Level 3 |   |   | Total |   |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |   | Total |   |
| Contingent Consideration             |   | $                                  | -      |   |                               | $      | - |   |   | $ | 967 |   |   | $ | 967 |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |
| Put Agreements                       |   |                               | -      |   |                               |   | - |   |   |   | 1,886 |   |   |   | 1,886 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Installment payable to related party |   |                               | -      |   |                               |   | - |   |   |   | 546 |   |   |   | 546 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                 |   | $                                  | -      |   |                               | $      | - |   |   | $ | 3,399 |   |   | $ | 3,399 |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |

|                             |   | 2016   |   |   | 2015   |   |
|----------------------------------|--------|--------|--------|--------|--------|--------|
|                             |   |   |   |   |   |   |
| Balance as of December, 31, 2015 |   | $      | -      |   |   | $      | - |   |
| Additions                        |   |   | 3,399  |   |   |   | - |   |
| Payments                         |   |   | -      |   |   |   | - |   |
| Balance as of December 31, 2016  |   | $      | 3,399  |   |   | $      | - |   |

----

TABLE OF CONTENTS

----

|                                                                   |   | As of December 31, |   |
|------------------------------------------------------------------------|--------|--------------------|--------|
|                                                                   |   | 2016               |   |   | 2015 |   |
|                                                                   |   |               |   |   |   |   |
| Line of credit                                                         |   | $                  | 350    |   |   | $ | - |   |
| Notes payable to directors                                             |   |               | 2,793  |   |   |   | 2,276 |   |
| Convertible debentures, gross                                          |   |               | 3,428  |   |   |   | 3,050 |   |
| Other debt                                                             |   |               | 1,361  |   |   |   | - |   |
|                                                                   |   |               | 7,932  |   |   |   | 5,326 |   |
|                                                                   |   |               |   |   |   |   |   |   |
| Less: unamortized portion of debt issuance costs                       |   |               | (14    | ) |   |   | (89 | ) |
| Less: unamortized portion of original issue discount                   |   |               | (77    | ) |   |   | (199 | ) |
| Total debt, net of debt issuance costs and original issue discount     |   |               | 7,841  |   |   |   | 5,038 |   |
|                                                                   |   |               |   |   |   |   |   |   |
| Less: short term portion                                               |   |               | (7,841 | ) |   |   | (601 | ) |
| Long-term debt, net of debt issuance costs and original issue discount |   | $                  | -      |   |   | $ | 4,437 |   |

----

TABLE OF CONTENTS

----

|                         |   | Years Ended December 31, |   |
|------------------------------|--------|--------------------------|--------|
|                         |   | 2016                     |   |   | 2015 |   |
|                         |   |                     |   |   |   |   |
| Contractual interest expense |   | $                        | 10     |   |   | $ | - |   |
| Interest paid                |   |                     | 10     |   |   |   | - |   |

|                                     |   | Years Ended December 31, |   |
|------------------------------------------|--------|--------------------------|--------|
|                                     |   | 2016                     |   |   | 2015 |   |
| Contractual interest expense             |   | $                        | 229    |   |   | $ | 88 |   |
| Amortization of original issue discounts |   |                     | 198    |   |   |   | - |   |
| Interest paid                            |   |                     | 272    |   |   |   | 10 |   |

| Risk-free interest rate      |   |   | 1.7  | %      |
|------------------------------|--------|--------|------|--------|
| Expected volatility          |   |   | 36.1 | %      |
| Dividend yield               |   |   | 0.0  | %      |
| Expected option life (years) |   |   | 7    |   |

----

TABLE OF CONTENTS

----

| Risk-free interest rate      |   |   | 2.1   | %      |
|------------------------------|--------|--------|-------|--------|
| Expected volatility          |   |   | 100.0 | %      |
| Dividend yield               |   |   | 0.0   | %      |
| Expected option life (years) |   |   | 7     |   |

|                                |   | As of December 31, |   |
|-------------------------------------|--------|--------------------|--------|
|                                |   | 2016               |   |   | 2015 |   |
|                                |   |               |   |   |   |   |
| Face amount of debentures           |   | $                  | 3,428  |   |   | $ | 3,050 |   |
| Unamortized original issue discount |   |               | (77    | ) |   |   | (89 | ) |
| Unamortized debt issuance costs     |   |               | (14    | ) |   |   | (199 | ) |
|                                |   |               | 3,337  |   |   |   | 2,762 |   |
| Less: short-term portion            |   |               | 3,337  |   |   |   | (383 | ) |
| Convertible Debentures, net         |   | $                  | -      |   |   | $ | 2,379 |   |

|                                       |   | Years Ended December 31, |   |
|--------------------------------------------|--------|--------------------------|--------|
|                                       |   | 2016                     |   |   | 2015 |   |
|                                       |   |                     |   |   |   |   |
| Contractual interest expense               |   | $                        | 163    |   |   | $ | 144 |   |
| Amortization of original issuance discount |   |                     | 250    |   |   |   | 213 |   |
| Amortization of debt issuance costs        |   |                     | 103    |   |   |   | 94 |   |
| Interest paid                              |   |                     | 81     |   |   |   | - |   |

| Risk-free interest rate      |   |   | 2.3   | %      |
|------------------------------|--------|--------|-------|--------|
| Expected volatility          |   |   | 100.0 | %      |
| Dividend yield               |   |   | 0.0   | %      |
| Expected option life (years) |   |   | 3     |   |

----

TABLE OF CONTENTS

----

| Risk-free interest rate      |   |   | 1.7  | %      |
|------------------------------|--------|--------|------|--------|
| Expected volatility          |   |   | 36.1 | %      |
| Dividend yield               |   |   | 0.0  | %      |
| Expected option life (years) |   |   | 5    |   |

----

TABLE OF CONTENTS

----

|                      |   | As of December 31, |   |
|---------------------------|--------|--------------------|--------|
|                      |   | 2016               |   |   | 2015 |   |
|                      |   |               |   |   |   |   |
| Short-term notes          |   | $                  | 950    |   |   | $ | - |   |
| Assumed convertible notes |   |               | 15     |   |   |   | - |   |
| Assumed notes payable     |   |               | 347    |   |   |   | - |   |
| Financing contracts       |   |               | 49     |   |   |   | - |   |
|                      |   |               | 1,361  |   |   |   | - |   |

|                                    |   | Years Ended December 31, |   |
|-----------------------------------------|--------|--------------------------|--------|
|                                    |   | 2016                     |   |   | 2015 |   |
|                                    |   |                     |   |   |   |   |
| Contractual interest expense            |   | $                        | 244    |   |   | $ | - |   |
| Amortization of original issue discount |   |                     | 87     |   |   |   | - |   |
| Interest paid                           |   |                     | 166    |   |   |   | - |   |
|                                    |   |                     |   |   |   |   |   |   |

----

TABLE OF CONTENTS

----

| Year       |   | Operating Leases |   |   | Operating Lease with Related Party |   |
|------------|--------|------------------|--------|--------|------------------------------------|--------|
| 2017       |   | $                | 343    |   |                               | $      | 71 |   |
| 2018       |   |             | 361    |   |                               |   | 73 |   |
| 2019       |   |             | 368    |   |                               |   | 75 |   |
| 2020       |   |             | 363    |   |                               |   | 78 |   |
| 2021       |   |             | 261    |   |                               |   | 80 |   |
| Thereafter |   |             | 1,347  |   |                               |   | 20 |   |
|       |   | $                | 3,043  |   |                               | $      | 397 |   |

| Year                         |   | Capital Leases |   |
|------------------------------|--------|----------------|--------|
| 2017                         |   | $              | 101    |   |
| 2018                         |   |           | 101    |   |
| 2019                         |   |           | 91     |   |
| Total minimum lease payments |   |           | 293    |   |
| Less: Interest               |   |           | (3     | ) |
|                         |   |           | 290    |   |
| Less: current portion        |   |           | (119   | ) |
| Capital lease obligation     |   | $              | 171    |   |

----

TABLE OF CONTENTS

----

| · | Series A- 7,150,000 shares authorized, 0 shares outstanding |
|--------|-------------------------------------------------------------|

| · | Series B- 2,000,000 shares authorized, 408,484 shares outstanding |
|--------|-------------------------------------------------------------------|

| · | Series C- 2,000,000 shares authorized, 1,471,121 shares outstanding |
|--------|---------------------------------------------------------------------|

| · | Series D- 2,000,000 shares authorized, 1,767,358 shares outstanding |
|--------|---------------------------------------------------------------------|

----

TABLE OF CONTENTS

----

|                                                                                       |   |      |      |   |           |   |      |   |   | Weighted     |   |
|--------------------------------------------------------------------------------------------|--------|-----------|-----------|--------|----------------|--------|-----------|--------|--------|--------------|--------|
|                                                                                       |   |      |      |   |           |   |      |   |   | average      |   |
|                                                                                       |   |      |      |   | Weighted       |   | Aggregate |   |   | remaining    |   |
|                                                                                       |   | Number of |      |   | average        |   | intrinsic |   |   | contractual  |   |
| (in thousands except number of options, exercise price and years) |   | options   |      |   | exercise price |   | value     |   |   | term (years) |   |
| Outstanding as of December 31, 2014                                                   |   |      | -         |   |           | $      | -         |   |   |         |   |   | - |   |
| Granted                                                                                    |   |      | 378,571   |   |           |   | 0.16      |   |   |         |   |   | 10.0 |   |
| Exercised                                                                                  |   |      | -         |   |           |   | -         |   |   |         |   |   | - |   |
| Forfeited or expired                                                                       |   |      | -         |   |           |   | -         |   |   |         |   |   | - |   |
| Outstanding as of December 31, 2015                                                   |   |      | 378,571   |   |           | $      | 0.16      |   |   | $            | 1,143  |   |   |   | 8.6 |   |
| Exercisable as of December 31, 2015                                                   |   |      | 378,571   |   |           | $      | 0.16      |   |   | $            | 1,143  |   |   |   | 8.6 |   |
|                                                                                       |   |      |      |   |           |   |      |   |   |         |   |   |   |   |   |   |
| Outstanding as of December 31, 2015                                                   |   |      | 378,571   |   |           | $      | 0.16      |   |   | $            | 1,143  |   |   |   | 8.6 |   |
| Granted                                                                                    |   |      | 1,258,137 |   |           |   | 6.05      |   |   |         |   |   |   |   | 7.3 |   |
| Exercised                                                                                  |   |      | (50,000   | )      |           |   | 0.16      |   |   | $            | 151    |   |   |   | - |   |
| Forfeited or expired                                                                       |   |      | (207,142  | )      |           |   | 1.00      |   |   |         |   |   |   |   | - |   |
| Outstanding as of December 31, 2016                                                   |   |      | 1,379,566 |   |           | $      | 5.40      |   |   | $            | 848    |   |   |   | 7.8 |   |
| Exercisable as of December 31, 2016                                                   |   |      | 674,290   |   |           | $      | 5.08      |   |   | $            | 628    |   |   |   | 7.6 |   |
| Remaining authorized options available for issue                                           |   |      | 98,847    |   |           |   |      |   |   |         |   |   |   |   |   |   |

----

TABLE OF CONTENTS

----

| Outstanding             |      |
|-------------------------|-----------|
| As of December 31, 2016 |      |
| Number ofshares         |      |   | Exercise price |   |   | Weighted averageremaining contractual term (years) |   |
|                    |      |   |   |   |
|                    | 150,000   |   |   | $ | 0.16 |   |   |   | 8.4 |   |
|                    | 769,701   |   |   | $ | 3.18 |   |   |   | 9.8 |   |
|                    | 173,189   |   |   | $ | 5.60 |   |   |   | 6.3 |   |
|                    | 286,676   |   |   | $ | 14.00 |   |   |   | 8.4 |   |
|                    | 1,379,566 |   |   |   |   |   |   |   | 7.8 |   |

| As of December 31, 2015 |    |
|-------------------------|---------|
| Number ofshares         |    |   | Exercise price |   |   | Weighted averageremaining contractual term (years) |   |
|                    |    |   |   |   |
|                    | 378,571 |   |   | $ | 0.16 |   |   |   | 8.6 |   |

| Exercisable             |    |
|-------------------------|---------|
| As of December 31, 2016 |    |
| Number ofshares         |    |   | Exercise price |   |   | Weighted averageremaining contractual term (years) |   |
|                    |    |   |   |   |
|                    | 150,000 |   |   | $ | 0.16 |   |   |   | 8.4 |   |
|                    | 256,748 |   |   | $ | 3.18 |   |   |   | 9.7 |   |
|                    | 138,015 |   |   | $ | 5.60 |   |   |   | 6.3 |   |
|                    | 129,527 |   |   | $ | 14.00 |   |   |   | 8.4 |   |
|                    | 674,290 |   |   |   |   |   |   |   | 7.6 |   |

| As of December 31, 2015 |    |
|-------------------------|---------|
| Number ofshares         |    |   | Exercise price |   |   | Weighted averageremaining contractual term (years) |   |
|                    |    |   |   |   |
|                    | 378,571 |   |   | $ | 0.16 |   |   |   | 8.6 |   |

----

TABLE OF CONTENTS

----

|                         |   | Year Ended December 31, |   |
|------------------------------|--------|-------------------------|--------|
|                         |   | 2016                    |   |   | 2015 |   |
| Risk-free interest rate      |   |                    | 1.6    | % |   |   | 2.3 | % |
| Expected volatility          |   |                    | 36.1   | % |   |   | 100.0 | % |
| Dividend yield               |   |                    | 0.0    | % |   |   | 0.0 | % |
| Expected option life (years) |   |                    | 10     |   |   |   | 10 |   |

|                                                                                       |   | Number of   |      |   |           |   |   |      |   |
|--------------------------------------------------------------------------------------------|--------|-------------|-----------|--------|----------------|--------|--------|-----------|--------|
|                                                                                       |   | shares      |      |   |           |   |   |      |   |
|                                                                                       |   | outstanding |      |   | Weighted       |   |   | Aggregate |   |
|                                                                                       |   | and         |      |   | average        |   |   | intrinsic |   |
| (in thousands except number of options, exercise price and years) |   | vested      |      |   | exercise price |   |   | value     |   |
|                                                                                       |   |        |      |   |           |   |   |      |   |
| Outstanding and exercisable as of December 31, 2014                                   |   |        | 156,524   |   |           | $      | 7.00   |      |   | $ | - |   |
| Granted                                                                                    |   |        | 677,962   |   |           |   | 3.86   |      |   |   |   |   |
| Exercised                                                                                  |   |        | (160,000  | )      |           |   | 0.01   |      |   | $ | 507 |   |
| Forfeited or expired                                                                       |   |        | -         |   |           |   | -      |      |   |   |   |   |
| Outstanding and exercisable as of December 31, 2015                                   |   |        | 674,486   |   |           | $      | 5.50   |      |   | $ | 460 |   |
| Granted                                                                                    |   |        | 1,896,314 |   |           |   | 7.36   |      |   |   |   |   |
| Exercised                                                                                  |   |        | (55,000   | )      |           |   | 0.01   |      |   | $ | 198 |   |
| Forfeited or expired                                                                       |   |        | -         |   |           |   | -      |      |   |   |   |   |
| Outstanding and exercisable as of December 31, 2016                                   |   |        | 2,515,800 |   |           | $      | 7.02   |      |   | $ | 378 |   |

----

TABLE OF CONTENTS

----

| As of December 31, 2016                  |      |
|------------------------------------------|-----------|
| Number ofsharesoutstandingandexercisable |      |   | Exercise price |   |   | Weighted averageremaining contractual term (years) |   |
|                                     |      |   |   |   |
|                                     | 105,000   |   |   | $ | 0.01 |   |   |   | 1.5 |   |
|                                     | 2,146,497 |   |   | $ | 7.00 |   |   |   | 5.6 |   |
|                                     | 264,303   |   |   | $ | 10.00 |   |   |   | 4.5 |   |
|                                     | 2,515,800 |   |   |   |   |   |   |   | 5.2 |   |

| As of December 31, 2015                  |     |
|------------------------------------------|----------|
| Number ofsharesoutstandingandexercisable |     |   | Exercise price |   |   | Weighted averageremaining contractual term (years) |   |
|                                     |     |   |   |   |
|                                     | 145,0001 |   |   | $ | 0.01 |   |   |   | 2.5 |   |
|                                     | 529,491  |   |   | $ | 7.00 |   |   |   | 6.3 |   |
|                                     | 674,491  |   |   |   |   |   |   |   | 5.6 |   |

|                                    |   | Number of Restricted Shares |     |
|-----------------------------------------|--------|-----------------------------|----------|
|                                    |   | 2016                        |     |   | 2015 |   |
|                                    |   |                        |     |   |   |   |   |   |
| Outstanding and not vested, January 1   |   |                        | 200,000  |   |   |   | 300,000 |   |
| Granted                                 |   |                        | -        |   |   |   | - |   |
| Forfeited                               |   |                        | -        |   |   |   | - |   |
| Vested                                  |   |                        | (200,000 | ) |   |   | (100,000 | ) |
| Outstanding and not vested, December 31 |   |                        | -        |   |   |   | 200,000 |   |

----

TABLE OF CONTENTS

----

|                                                                 |   | Years ended December 31, |      |
|---------------------------------------------------------------------------|--------|--------------------------|-----------|
|                                                                      |   | 2016                     |      |   | 2015 |   |
| Basic and diluted net loss attributable to common stockholders per share: |   |                     |      |   |
| Numerator:                                                                |   |                     |      |   |   |   |
| Allocation of distributed net loss attributable to common stockholders    |   | $                        | (11,746   | ) |   | $ | (4,085 | ) |
| Denominator:                                                              |   |                     |      |   |   |   |   |   |
| Weighted-average common shares outstanding                                |   |                     | 4,687,039 |   |   |   | 1,766,030 |   |
| Basic and diluted net loss per share                                      |   | $                        | (2.51     | ) |   | $ | (2.31 | ) |

|                        |   | As of December 31, |      |
|-----------------------------|--------|--------------------|-----------|
|                        |   | 2016               |      |   | 2015 |   |
| Restricted stock            |   |               | -         |   |   |   | 200,000 |   |
| Non-qualified stock options |   |               | 1,379,566 |   |   |   | 378,571 |   |
| Stock warrants              |   |               | 2,515,800 |   |   |   | 674,486 |   |
|                        |   |               | 3,895,366 |   |   |   | 1,253,057 |   |

|                               |   | 2016   |   |   | 2015   |   |
|------------------------------------|--------|--------|--------|--------|--------|--------|
|                               |   |   |   |   |   |   |
| Federal statutory tax benefit rate |   |   | (34.0  | )%     |   |   | (34.0 | )% |
| State tax, net of federal benefit  |   |   | (2.4   | )      |   |   | (2.1 | ) |
| Permanent differences              |   |   | 9.0    |   |   |   | 8.5 |   |
| Other                              |   |   | (14.1  | )      |   |   | (11.6 | ) |
| Change in valuation allowance      |   |   | 24.9   |   |   |   | 39.2 |   |
|                               |   |   | (16.6  | )%     |   |   | - | % |

----

TABLE OF CONTENTS

----

|                             |   | 2016   |   |   | 2015   |   |
|----------------------------------|--------|--------|--------|--------|--------|--------|
| Deferred income tax assets:      |   |   |   |   |   |   |
| Net operating loss carryforwards |   | $      | 8,685  |   |   | $      | 1,106 |   |
| R&D credit carryforwards     |   |   | 395    |   |   |   | 395 |   |
| Start-up costs                   |   |   | 14     |   |   |   | 15 |   |
| Accruals and reserves            |   |   | 759    |   |   |   | 292 |   |
| Depreciation                     |   |   | 27     |   |   |   | 17 |   |
| Deferred revenue                 |   |   | 23     |   |   |   | - |   |
| Deferred rent                    |   |   | 25     |   |   |   | - |   |
|                             |   |   | 9,928  |   |   |   | 1,825 |   |
| Deferred income tax liabilities: |   |   |   |   |   |   |   |   |
| Amortization                     |   |   | (5,142 | )      |   |   | (286 | ) |
| Non-cash compensation costs      |   |   | -      |   |   |   | (12 | ) |
| Deferred revenue                 |   |   | -      |   |   |   | (10 | ) |
| Investment in Partnership        |   |   | (46    | )      |   |   | - |   |
|                             |   |   | (5,188 | )      |   |   | (308 | ) |
| Net deferred income tax assets   |   |   | 4,740  |   |   |   | 1,517 |   |
| Less: Valuation allowance        |   |   | (4,740 | )      |   |   | (1,517 | ) |
| Net deferred income tax assets   |   | $      | -      |   |   | $      | - |   |
|                             |   |   |   |   |   |   |   |   |

|               |   | Net Operating Losses |   |   | Research and |   |
|--------------------|--------|----------------------|--------|--------|--------------|--------|
|               |   |                 |   |   |         |   |   | Development |   |
| Year of Expiration |   | Federal              |   |   | State        |   |   | Credits |   |
| 2025               |   |                 | 173    |   |         |   | - |   |   |   | 24 |   |
| 2026               |   |                 | -      |   |         |   | - |   |   |   | 39 |   |
| 2027               |   |                 | 312    |   |         |   | - |   |   |   | 51 |   |
| 2028               |   |                 | 40     |   |         |   | - |   |   |   | 44 |   |
| 2029               |   |                 | 40     |   |         |   | 180 |   |   |   | 45 |   |
| 2030               |   |                 | 51     |   |         |   | 711 |   |   |   | 39 |   |
| 2031               |   |                 | 856    |   |         |   | 3,833 |   |   |   | 16 |   |
| 2032               |   |                 | 2,420  |   |         |   | 2,421 |   |   |   | 21 |   |
| 2033               |   |                 | 2,607  |   |         |   | 2,528 |   |   |   | 27 |   |
| 2034               |   |                 | 3,864  |   |         |   | 3,645 |   |   |   | 44 |   |
| 2035               |   |                 | 4,240  |   |         |   | 2,403 |   |   |   | 45 |   |
| 2036               |   |                 | 8,174  |   |         |   | 444 |   |   |   | - |   |
|               |   | $                    | 22,777 |   |         | $      | 16,165 |   |   | $ | 395 |   |

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

|                                             |   | For the year ended December 31, 2016 |   |
|--------------------------------------------------|--------|--------------------------------------|--------|
|                                             |   | Sal-Tech                             |   |   | AGL |   |   | LMID |   |   | Corporate |   |   | Total |   |
|                                             |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Revenue                                    |   | $                                    | 959    |   |   | $ | 1,234 |   |   | $ | 118 |   |   | $ | - |   |   | $ | 2,311 |   |
|  Loss from operations                       |   |                                 | (951   | ) |   |   | (17 | ) |   |   | (2,671 | ) |   |   | (6,447 | ) |   |   | (10,086 | ) |
|  Net income (loss)                          |   |                                 | (952   | ) |   |   | 405 |   |   |   | (2,677 | ) |   |   | (7,552 | ) |   |   | (10,775 | ) |
|  Total Assets                               |   |                                 | 1,560  |   |   |   | 2,860 |   |   |   | 2,735 |   |   |   | 20,431 |   |   |   | 29,769 |   |
|  Depreciation and amortization              |   |                                 | 104    |   |   |   | 209 |   |   |   | 783 |   |   |   | 153 |   |   |   | 1,249 |   |
|  Capital expenditures                       |   |                                 | (4     | ) |   |   | (3 | ) |   |   | (73 | ) |   |   | (29 | ) |   |   | (109 | ) |
|  Net loss on Investment in LifeMed ID, Inc. |   |                                 | -      |   |   |   | - |   |   |   | - |   |   |   | (438 | ) |   |   | (438 | ) |
|  Gain on extinguishment of debt             |   |                                 | -      |   |   |   | 569 |   |   |   | - |   |   |   | 173 |   |   |   | 742 |   |
|  Interest expense, net of interest income   |   |                                 | -      |   |   |   | (59 | ) |   |   | (6 | ) |   |   | (2,962 | ) |   |   | (3,027 | ) |
|  Income tax benefit                         |   |                                 | -      |   |   |   | - |   |   |   | - |   |   |   | 2,122 |   |   |   | 2,122 |  |

|                                             |   | For the year ended December 31, 2015 |   |
|--------------------------------------------------|--------|--------------------------------------|--------|
|                                             |   | Sal-Tech                             |   |   | AGL |   |   | LMID |   |   | Corporate |   |   | Total |   |
|                                             |   |                                 |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Revenue                                    |   | $                                    | 245    |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | 245 |   |
|  Loss from operations                       |   |                                 | (337   | ) |   |   | - |   |   |   | - |   |   |   | (3,253 | ) |   |   | (3,590 | ) |
|  Net income (loss)                          |   |                                 | 65     |   |   |   | - |   |   |   | - |   |   |   | (3,745 | ) |   |   | (3,680 | ) |
|  Total Assets                               |   |                                 | 2,698  |   |   |   | - |   |   |   | - |   |   |   | 7,981 |   |   |   | 10,679 |   |
|  Depreciation and amortization              |   |                                 | 26     |   |   |   | - |   |   |   | - |   |   |   | 14 |   |   |   | 40 |   |
|  Capital expenditures                       |   |                                 | (3     | ) |   |   | - |   |   |   | - |   |   |   | (75 | ) |   |   | (78 | ) |
|  Net loss on Investment in LifeMed ID, Inc. |   |                                 | -      |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|  Gain on extinguishment of debt             |   |                                 | -      |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|  Interest expense, net of interest income   |   |                                 | (1     | ) |   |   | - |   |   |   | - |   |   |   | (493 | ) |   |   | (494 | ) |
|  Income tax provision (benefit)             |   |                                 | -      |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |

----

TABLE OF CONTENTS

----

|                                                                                    |   | For the Year Ended December 31, 2016 |      |   | For the Year Ended December 31, 2015 |   |
|-----------------------------------------------------------------------------------------|--------|--------------------------------------|-----------|--------|--------------------------------------|--------|
|                                                                                    |   |                                 |      |   |                                 |   |
| Pro forma revenue                                                                       |   | $                                    | 2,620     |   |                                 | $      | 1,954 |   |
|                                                                                    |   |                                 |      |   |                                 |   |   |   |
| Pro forma loss from operations                                                          |   | $                                    | (14,547   | )      |                                 | $      | (13,062 | ) |
|                                                                                    |   |                                 |      |   |                                 |   |   |   |
| Pro forma net loss before non-controlling interest in subsidiary and income tax benefit |   | $                                    | (17,359   | )      |                                 | $      | (13,481 | ) |
|                                                                                    |   |                                 |      |   |                                 |   |   |   |
| Pro forma net loss attributable to common stockholders                                  |   | $                                    | (16,309   | )      |                                 | $      | (13,886 | ) |
|                                                                                    |   |                                 |      |   |                                 |   |   |   |
| Pro forma loss per common share – basic and diluted                               |   | $                                    | (2.75     | )      |                                 | $      | (3.41 | ) |
|                                                                                    |   |                                 |      |   |                                 |   |   |   |
| Pro forma weighted average common shares outstanding – basic and diluted          |   |                                 | 5,938,157 |   |                                 |   | 4,069,964 |   |

----

TABLE OF CONTENTS

----

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

|                 | ORANGEHOOK, INC. |
|----------------------|------------------|
|                 |             |
| Date: April 17, 2017 | By:              | /s/  James L. Mandel                                                             |
|                 |             |        James L. Mandel |
|                 |             |        Chief Executive Officer |
|                 |             |   |
|                 |             |   |
| Date: April 17, 2017 | By:              | /s/  David C. Carlson                                                             |
|                 |             |        David C. Carlson |
|                 |             |        Chief Financial Officer |

|                                                      |   | Title                       |   | Date           |
|-----------------------------------------------------------|--------|-----------------------------|--------|----------------|
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  James L. Mandel                                 |   | Chief Executive Officer and |   | April 17, 2017 |
|        James L. Mandel      |   | Director                    |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  David C. Carlson                                |   | Chief Financial Officer     |   | April 17, 2017 |
|        David C. Carlson     |   |                        |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  Donald Miller                                   |   | Director (Chairman)         |   | April 17, 2017 |
|        Donald Miller        |   |                        |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/   Whitney Peyton                            |   | Director                    |   | April 17, 2017 |
|         Whitney Peyton |   |                        |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  Jonathan Dodge                                  |   | Director                    |   | April 17, 2017 |
|        Jonathan Dodge       |   |                        |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  Salvatore Fazzolari                             |   | Director                    |   | April 17, 2017 |
|        Salvatore Fazzolari  |   |                        |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  Richard Resnick                                 |   | Director                    |   | April 17, 2017 |
|        Richard Resnick      |   |                        |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  David Batchelor                                 |   | Director                    |   | April 17, 2017 |
|        David Batchelor      |   |                        |   |           |
|                                                      |   |                        |   |           |
|                                                      |   |                        |   |           |
| /s/  Jeffrey Hattara                                 |   | Director                    |   | April 17, 2017 |
|        Jeffrey Hattara      |   |                        |   |           |

----

TABLE OF CONTENTS

| Exhibit Number |   | Description                                                                                                                                                                                       |
|----------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                |
|           |   |                                                                                                                                                                                              |   |
| 2.1            |   | Plan of Merger between Nuvel Holdings, Inc. and HRMY Sub, Inc., dated March 20, 2012.(1)                                                                                                          |
| 2.2            |   | Agreement and Plan of Merger dated July 1, 2016 by and among Nuvel Holdings, Inc., OH Acquisition Corp., and OrangeHook, Inc.(2)                                                                  |
| 2.3            |   | Amendment No. 1 to Agreement and Plan of Merger dated October 14, 2016 by and among OrangeHook, Inc., Nuvel Holdings, Inc., and OH Acquisition Corp.(3)                                           |
| 2.4            |   | Agreement and Plan of Merger dated October 1, 2015 by and among OrangeHook, Inc.,Salamander Technologies, LLC, Salamander Technologies, Inc., and the other parties named therein.(15)       |
| 2.5            |   | Membership Unit Purchase Agreement dated January 4, 2016 by and among OrangeHook, Inc., Agilivant, LLC, and the members of the Agilivant, LLC. (15)                                               |
| 2.6            |   | Amended and Restated Agreement and Plan of Merger dated May 31, 2016 by and among OrangeHook, Inc., OH Solutions, Inc., LifeMed ID, Inc., and the principal shareholders of LifeMed ID, Inc. (15) |
| 2.7            |   | Purchase Agreement dated December 31, 2013 by and among TruSec ID, Inc., and the two parties named therein. (15)                                                                                  |
| 2.8            |   | First Amendment to Purchase Agreement dated July 31, 2015 Salamander Technologies, Inc., TruSec ID, Inc., OrangeHook, Inc., and the other parties named therein. (15)                             |
| 2.9            |   | Purchase Agreement dated December 31, 2013 by and among Salamander Technologies, Inc., TruSec ID, Inc., and the numerous other parties named therein. (15)                                        |
| 2.10           |   | Share Exchange Agreement by and among Nuvel Holdings, Inc., certain former shareholders of Nuvel Holdings, Inc., Nuvel, Inc. and Shareholders of Nuvel, Inc., dated December 30, 2011.(10)        |
| 2.11           |   | Asset Purchase Agreement, dated May 2, 2016 between Spring Grove Finance, S.A. and OrangeHook. (15)                                                                                               |
| 3.1            |   | Articles of Incorporation of Nuvel Holdings, Inc., dated June 15, 2010.(4)                                                                                                                        |
| 3.2            |   | Articles of Merger of Nuvel Holdings, Inc. filed with the State of Florida on March 21, 2012.(1)                                                                                                  |
| 3.3            |   | Articles of Amendment to Articles of Incorporation, filed with the State of Florida on August 5, 2014.(5)                                                                                         |
| 3.4            |   | Bylaws of Nuvel Holdings, Inc.(4)                                                                                                                                                                 |
| 4.1            |   | Certificate of Designations, Preferences and Rights of Series A Preferred Stock, filed with the State of Florida on August 10, 2012.(6)                                                           |
| 4.2            |   | Certificate of Designations, Preferences and Rights of Series B Preferred Stock, filed with the State of Florida on May 19, 2014.(5)                                                              |
| 4.3            |   | Certificate of Designations, Preferences and Rights of Series C Preferred Stock, filed with the State of Florida on May 22, 2014.(5)                                                              |
| 4.4            |   | Certificate of Designations, Preferences and Rights of Series D Preferred Stock, filed with the State of Florida on May 2, 2014.(5)                                                               |
| 4.5            |   | Certificate of Designation of Series OH-1 Convertible Preferred Stock of Nuvel Holdings, Inc.(3)                                                                                                  |
| 4.6            |   | Certificate of Designation of Series OH-2 Convertible Preferred Stock of Nuvel Holdings, Inc.(3)                                                                                                  |
| 4.7            |   | Amendment to Certificate of Designation of Series OH-2 Convertible Preferred Stock of Nuvel Holdings, Inc.(19)                                                                                    |
| 10.1           |   | Form of Bridge Notes pursuant to an Amended and Restated Subscription Agreement, dated December 30, 2011.(7)                                                                                 |
| 10.2           |   | Form of Bridge Warrants pursuant to an Amended and Restated Subscription Agreement, dated December 30, 2011.(7)                                                                              |
| 10.3           |   | Form of Paragon Note issued to Paragon Capital Offshore LP, dated December 30, 2011.(7)                                                                                                           |
| 10.4           |   | Form of Paragon Warrant issued to Paragon Capital LP, dated December 30, 2011.(7)                                                                                                                 |
| 10.5           |   | Form of Series A Warrant issued to Series A Preferred Investors in August 2012. (6)                                                                                                               |
| 10.6           |   | Form of Note issued to Alpha Capital Anstalt in November 2012.(8)                                                                                                                                 |
| 10.7           |   | Form of Warrant issued to Alpha Capital Anstalt in November 2012.(8)                                                                                                                              |
| 10.8           |   | Form of Extension Warrant issued to Bridge Note Investors in November 2012.(5)                                                                                                                    |
| 10.9           |   | Form of New Bridge Note issued pursuant to the New Bridge Subscription Agreement.(9)                                                                                                              |

----

TABLE OF CONTENTS

| Exhibit Number |        | Description                                                                                                                                                   |
|----------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           |   |                                                                                                                                                          |
| 10.10          |   | Form of New Bridge Warrant issued pursuant to the New Bridge Subscription Agreement.(9)                                                                       |
| 10.11          |   | Form of OrangeHook, Inc. Convertible Promissory Note for the 2015 Convertible Note Offering.(15)                                                              |
| 10.12          |   | Form of OrangeHook, Inc. Amended and Restated Convertible Promissory Note. (15)                                                                               |
| 10.13          |   | Form of OrangeHook, Inc. Promissory Note. (15)                                                                                                                |
| 10.14          |   | Form of OrangeHook, Inc. Warrant Agreement. (15)                                                                                                              |
| 10.15*         |   | OrangeHook, Inc. 2016 Equity Incentive Plan.(15)                                                                                                              |
| 10.16*         |   | Form of OrangeHook, Inc. Incentive Stock Option Agreement. (15)                                                                                               |
| 10.17*         |   | Form of OrangeHook, Inc. Restricted Stock Agreement. (15)                                                                                                     |
| 10.18*         |   | Form of OrangeHook, Inc. Nonqualified Stock Option Agreement. (15)                                                                                            |
| 10.19*         |   | Form of OrangeHook, Inc. Restricted Stock Unit Agreement. (15)                                                                                                |
| 10.20          |   | Business Loan Agreement, dated March 30, 2016, between OrangeHook, Inc. and Signature Bank. (15)                                                              |
| 10.21          |   | Promissory Note, dated March 30, 2016, issued by OrangeHook, Inc. to Signature Bank. (15)                                                                     |
| 10.22          |   | Change in Terms Agreement, dated July 8, 2016, between OrangeHook, Inc. and Signature Bank. (15)                                                              |
| 10.23          |   | Change in Terms Agreement, dated September 28, 2016, between OrangeHook, Inc. and Signature Bank. (15)                                                        |
| 10.24*         |   | Employment Agreement dated July 1, 2015 between OrangeHook and James Mandel. (15)                                                                             |
| 10.25*         |   | Employment Agreement dated February 2, 2015 between OrangeHook and David Carlson. (15)                                                                        |
| 10.26*         |   | Employment Agreement dated April 23, 2014 between OrangeHook and Robert F. Riess. (15)                                                                        |
| 10.27*         |   | Amended and Restated Employment Agreement dated March 15, 2016 by and among LifeMed ID, Inc., OrangeHook, Inc. and David Batchelor. (15)                      |
| 10.28*         |   | Amendment No. 1 to Employment Agreement dated May 31, 2016 by and among LifeMed ID, Inc., OrangeHook, Inc. and David Batchelor. (15)                          |
| 10.29*         |   | Registration Rights and Put Option Agreement entered into as of March 23, 2016 between OrangeHook, Inc. and David Batchelor. (15)                             |
| 10.30*         |   | Amendment to Registration Rights and Put Option Agreement dated May 31, 2016 between OrangeHook, Inc. and David Batchelor. (15)                               |
| 10.31*         |   | Nonqualified Stock Option Agreement, dated May 31, 2016, between OrangeHook, Inc. and David Batchelor. (15)                                                   |
| 10.32*         |   | Employment Agreement, effective July 1, 2015, between OrangeHook, Inc. and Jeffrey Hattara.(15)                                                               |
| 10.33*         |   | Employment Agreement, effective October 21, 2016, between OrangeHook, Inc. and Colleen Davenport. (15)                                                        |
| 10.34*         |   | Amendment No. 1 to Employment Agreement, dated November 29, 2016, between OrangeHook, Inc. and Colleen Davenport. (15)                                        |
| 10.35*         |   | Employment Agreement, effective December 1, 2016, between Nuvel Holdings, Inc. and Richard Resnick. (15)                                                      |
| 10.36*         |   | Employment Agreement, effective November 9, 2016, between OrangeHook, Inc. and Robert Philbin. (15)                                                           |
| 10.37          |   | Commercial Lease, dated October 1, 2015, between Milwhe Properties, LLC and Salamander. (15)                                                                  |
| 10.38          |   | Commercial Lease, dated October 1, 2015, between OrangeHook and Norway, LLC. (15)                                                                             |
| 10.39          |   | Commercial Lease, dated December 1, 2015, between OrangeHook and Norway, LLC. (15)                                                                            |
| 10.40          |   | Sublease Agreement, dated December 15, 2014, between OrangeHook and Manada Technologies, Inc. (15)                                                            |
| 10.41          |   | Office Building Lease, dated March 7, 2016, between BEP Roseville Investors LLC and OrangeHook, Inc. (15)                                                     |
| 10.42          |   | Lease Agreement, dated May 6, 2010, between Stonemill Business Park, L.L.C. and Agilivant, LLC, as assignee. (15)                                             |
| 10.43          |   | Restatement of and First Amendment to Lease between Stonemill Business Park, LLC and Agilivant, LLC, dated September 25, 2013. (15)                           |
| 10.44          |   | Business Partnership Agreement, dated March 10, 2016, between Lenovo PC HK Limited, LifeMed ID, Inc. and OrangeHook, Inc.(14) (16)                            |
| 10.45          |   | Amendment 2 to Business Partner Agreement MA-13-000677, dated September 1, 2016, between Lenovo PC HK Limited, LifeMed ID, Inc. and OrangeHook, Inc.(14) (15) |
| 10.46          |   | Commercial Promissory Note, dated July 26, 2016, issued by OrangeHook to MEZ Capital, LLC. (15)                                                               |

----

TABLE OF CONTENTS

| Exhibit Number |   | Description                                                                                                                                                                                 |
|----------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           |   |                                                                                                                                                                                        |
| 10.47          |   | Letter Agreement re: Satisfaction of Obligations Owed to LifeMed ID, Inc., dated November 2, 2016, between OrangeHook, Inc. and David Batchelor. (15)                                       |
| 10.48*         |   | Restricted Stock Agreement, dated December 1, 2016, between Nuvel and Richard Resnick. (15)                                                                                                 |
| 10.49          |   | Security Agreement between Nuvel, Inc. and Paragon Capital Offshore LP, dated December 30, 2011. (7)                                                                                        |
| 10.50          |   | Form of Guaranty of Nuvel Holdings, Inc. for the Paragon Note, dated December 30, 2011. (7)                                                                                                 |
| 10.51          |   | Form of Lockup Agreement between certain shareholders and Nuvel Holdings, Inc., dated December 30, 2011.(7)                                                                                 |
| 10.52*         |   | Form of Nuvel Holdings, Inc. Employment Agreement.(7)                                                                                                                                       |
| 10.53          |   | Form of Nuvel Holdings, Inc. Proprietary Information and Inventions Agreement.(7)                                                                                                           |
| 10.54          |   | Assignment and Assumption Agreement between Nuvel Holdings, Inc. and Sahej Holdings, Inc., dated February 1, 2012.(7)                                                                       |
| 10.55          |   | Third Amendment to the Subscription Agreement between Nuvel Holdings, Inc. and the investor named therein, dated December 30, 2011.(1)                                                      |
| 10.56          |   | Subscription Agreement between Nuvel Holdings, Inc. and Alpha Capital Anstalt, dated November 21, 2012.(8)                                                                                  |
| 10.57          |   | Security Agreement between Nuvel Holdings, Inc. and Alpha Capital Anstalt, dated November 21, 2012.(8)                                                                                 |
| 10.58          |   | Lockup Agreement between Nuvel Holdings, Inc. and Alpha Capital Anstalt, dated November 21, 2012.(8)                                                                                   |
| 10.59          |   | Form of Extension and Amendment Agreement, between Nuvel Holdings, Inc. and Bridge Investors, dated November 16, 2012.(5)                                                                   |
| 10.60          |   | First Amendment to Subscription Agreement, between Nuvel Holdings, Inc. and Alpha Capital Anstalt, dated April 8, 2014.(5)                                                                  |
| 10.61          |   | First Amendment to Secured Convertible Promissory Notes, among Nuvel Holdings, Inc., Alpha Capital Anstalt and Chi Squared Capital Inc., dated April 8, 2014.(5)                            |
| 10.62          |   | First Amendment to Security Agreement, between Nuvel Holdings, Inc. and Alpha Capital Anstalt, dated April 8, 2014.(5)                                                                      |
| 10.63          |   | Note Waiver and Amendment Agreement, dated May 5, 2014.(5)                                                                                                                                  |
| 10.64          |   | New Bridge Agreement, dated May 5, 2014.(9)                                                                                                                                            |
| 10.65          |   | Contractor Agreement, dated March 11, 2014, between Nuvel Holdings, Inc. and Richard Resnick.(11)                                                                                      |
| 10.66          |   | Separation Agreement between Nuvel Holdings Inc. and Jay Elliot.(12)                                                                                                                        |
| 10.67          |   | ACA Note Conversion Agreement.(13)                                                                                                                                                          |
| 10.68          |   | Chi Note Conversion Agreement.(13)                                                                                                                                                          |
| 10.69          |   | Settlement Agreement with Apptology.(13)                                                                                                                                                    |
| 10.70          |   | Form of Indemnification Agreement for Executive Officers and Directors. (15)                                                                                                                |
| 10.71          |   | Form of Indemnification Agreement for James Mandel and Richard Resnick. (15)                                                                                                                |
| 10.72*         |   | Nonqualified Stock Option Agreement, dated December 1, 2016, between Nuvel Holdings, Inc. and Richard Resnick. (15)                                                                         |
| 10.73          |   | OrangeHook, Inc. 2016 Equity Incentive Plan. (17)                                                                                                                                           |
| 10.74          |   | Amendment 1 to Business Partner Agreement MA-13-000677, dated August 19, 2016, between Lenovo PC HK Limited, LifeMed ID, Inc. and OrangeHook, Inc.(14)                                      |
| 10.75          |   | AGL System Rights Agreement, dated April 19, 2016, between Agilivant, LLC, Corporate Resources Australia Limited, and WAIV International Pty Ltd. (14)                                      |
| 10.76          |   | Lender Agreement, dated December 6, 2016, between OrangeHook, Inc. and Richard Bernstein.                                                                                                   |
| 10.77          |   | Lender Agreement, dated January 19, 2017, between OrangeHook, Inc. and Richard Bernstein.                                                                                                   |
| 10.78          |   | Amendment to Lender Agreement, dated January 25, 2017, between OrangeHook, Inc. and Richard Bernstein.                                                                                      |
| 10.79          |   | Modification of Commercial Promissory Note, dated December 23, 2016, between OrangeHook, Inc. and MEZ Capital, LLC.                                                                         |
| 10.80          |   | Participation and Repayment Priority Agreement, dated March 31, 2017, between OrangeHook, Inc., James L. Mandel, Donald M. Miller, Whitney E. Peyton, Jeffrey J. Hattara and Thomas Hudson. |
| 14.1           |   | Code of Ethical Business Conduct for Senior Financials Officers(18)                                                                                                                         |

----

TABLE OF CONTENTS

| Exhibit Number |   | Description                                                                                                                                                                        |
|----------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           |   |                                                                                                                                                                               |
| 21.1           |   | Significant Subsidiaries of OrangeHook, Inc.                                                                                                                                       |
| 31.1           |   | Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a)                                                                                             |
| 31.2           |   | Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a)                                                                                             |
| 32.1           |   | Certification of principal executive officer and principal financial officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |

| *    | Management compensatory plan or arrangement.                                                                                                                                                                                        |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1)  | Included as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2011, filed on April 13, 2012.                                                                                                             |
| (2)  | Included as an exhibit to the Current Report on Form 8-K, filed on July 8, 2016.                                                                                                                                                    |
| (3)  | Included as an exhibit to the Current Report on Form 8-K, filed on October 14, 2016.                                                                                                                                                |
| (4)  | Included as an exhibit to the Registration Statement on Form S-1, filed on November 5, 2010.                                                                                                                                        |
| (5)  | Included as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2013, filed on November 25, 2014.                                                                                                          |
| (6)  | Included as an exhibit to the Current Report on Form 8-K, filed on August 20, 2012.                                                                                                                                                 |
| (7)  | Included as an exhibit to Amendment No. 2 to the Current Report on Form 8-K/A, filed on March 19, 2012.                                                                                                                             |
| (8)  | Included as an exhibit to the Current Report on Form 8-K, filed on November 28, 2012.                                                                                                                                               |
| (9)  | Included as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2014, filed on June 23, 2015.                                                                                                              |
| (10) | Included as an exhibit to the Current Report on Form 8-K, filed on January 6, 2012.                                                                                                                                                 |
| (11) | Included as an exhibit to the Current Report on Form 8-K, filed on February 27, 2015.                                                                                                                                               |
| (12) | Included as an exhibit to the Current Report on Form 8-K, filed on August 4, 2015.                                                                                                                                                  |
| (13) | Included as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2015, filed on April 5, 2016.                                                                                                              |
| (14) | Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Exchange Act. The entire exhibit has been separately filed with the Securities and Exchange Commission. |
| (15) | Included as an exhibit to the Current Report on Form 8-K, filed on December 5, 2016.                                                                                                                                                |
| (16) | Included as an exhibit to the Current Report on Form 8-K, filed on April 11, 2017.                                                                                                                                                  |
| (17) | Included as an exhibit to the Current Report on Form 8-K, filed on January 3, 2017.                                                                                                                                                 |
| (18) | Included as an exhibit to the Current Report on Form 8-K, filed on March 7, 2017.                                                                                                                                                   |
| (19) | Included as an exhibit to the Current Report on Form 8-K, filed on January 25, 2017.                                                                                                                                                |

----